WO2009046445A1 - Sequencing nucleic acid polymers with electron microscopy - Google Patents
Sequencing nucleic acid polymers with electron microscopy Download PDFInfo
- Publication number
- WO2009046445A1 WO2009046445A1 PCT/US2008/078986 US2008078986W WO2009046445A1 WO 2009046445 A1 WO2009046445 A1 WO 2009046445A1 US 2008078986 W US2008078986 W US 2008078986W WO 2009046445 A1 WO2009046445 A1 WO 2009046445A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- strand
- needle
- dna
- labeled
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/60—Detection means characterised by use of a special device
- C12Q2565/601—Detection means characterised by use of a special device being a microscope, e.g. atomic force microscopy [AFM]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Definitions
- the invention relates to methods of sequencing nucleic acids
- TEM transmission electron microscope
- atoms of low atomic number (Z) produce very little contrast and are essentially invisible in the electron microscope
- Ordinary DNA comprising low-Z hydrogen, carbon, nitrogen oxygen, and phosphorus atoms shows almost no contrast in an electron microscope and is almost impossible to see against a supporting background
- the bases may be labeled with high-Z atoms or otherwise rendered detectable by TEM
- the invention provides methods for using an electron microscope to sequence by direct inspection of labeled, stretched nucleic acid, such as DNA
- the methods, devices, and compositions of the invention allow controllable placement of a nucleic acid on a substrate, so that there is consistent base-to-base spacing, allowing for accurate nucleic acid sequencing information to be obtained using electron microscopy
- the invention may be implemented in a number of ways
- a method for obtaining sequence information of a DNA polymer strand may include providing a solution comprising a DNA polymer strand, where the DNA polymer strand has been treated such that a plurality of DNA bases have been labeled with an contrast agent with base specificity or base selectivity, introducing a DNA binding tool into the solution and binding a section of the DNA polymer onto the tool, removing the tool from the solution, stretching the labeled DNA polymer strand into space such that the labeled DNA polymer strand is suspended between an air/solvent interface and the tool, depositing the stretched labeled DNA polymer strand onto a substrate, imaging the labeled DNA d polymer strand using electron microscopy such that positions of labeled and unlabeled bases are determined, and correlating the positions of labeled and unlabeled bases with the sequence of the DNA polymer [0010]
- the method may further include denaturing the DNA strand to generate single stranded DNA prior to labeling with the contrast agent.
- the DNA may be high molecular weight DNA having greater than about 100 kb
- the stretching step may result in consistent base-to-base spacing in the DNA polymer strand
- the base-to-base spacing between the bases may be is in a range of about 3 A to about 7 A, and specifically be about 5 A
- the DNA polymer strand may be stretched to a length of at least about 2 ⁇ m
- the subset of bases comprises thymines and cytosines
- the subset of bases comprises adenine and guanine
- the tool may be a needle such that a tip of the needle has been functionalized with a first coating that binds to a DNA polymer strand
- the needle may be fabricated from glass, gold, tungsten, PMMA polystyrene PVC or silicon
- the coating may be a compound such as PMMA, polystyrene, PVB, and oligonucleotides
- the needle may be functionalized with a second coating that does not bind to nucleic acids
- the second coating may be at least one of octanethiol, hexanethiol, nonanethiol, decanethiol, and septanethiol
- the tip of the needle has a radius of curvature that is less than about 200 nm
- the needle may be moved into and out of the solution at a rate in a range of about 1 nanometers/second to about 100 meters/second Specifically, the needle may be moved into the solution at a depth having a range of about 1 A
- the contrast agent may be a high-Z atom labeling compound
- the high-Z atom may be Os-bipy, mercuric acetate and platinum dimethylsulfoxide
- the contrast agent may be a high-Z atom cluster label
- the DNA polymer strand may be attached to a substrate by employing shelf threading
- the DNA polymer strand may be attached to either a support substrate or an imaging substrate
- the DNA polymer strand may be attached to a support substrate by employing shelf threading followed by transferring the labeled DNA polymer strand on the support substrate to an imaging substrate by employing transfer printing
- the DNA polymer strand may be attached to a support substrate by employing gap threading following by transferring the labeled DNA polymer strand on the support substrate to an imaging substrate by employing swipe printing
- the DNA polymer strands may be a plurality of DNA polymer strands and may be positioned as an array of parallel strands on a substrate
- the stretched labeled DNA polymer strand may be single stranded
- a method for obtaining a nucleic acid sequence information may include determining by electron microscopy the positions of labeled and unlabeled bases of a nucleic acid strand within a region of at least 1000 contiguous
- the nucleic acid sequence may be obtained at a rate at least 1 ,000 bases/second
- the nucleic acid strand may have a length of at least about 100 ⁇ m when extended
- the nucleic acid may have base-to-base spacing in a range of 3 A to about 7 A between the bases, and specifically, about 5 A
- the nucleic acid sequence may be a DNA sequence
- an article of manufacture may include a liquid having a plurality of nucleic acid polymer strands, a tool and a single nucleic acid polymer strand having a first end in the liquid and a second end attached to the tool, where at least a portion of the single nucleic acid polymer strand is suspended in space between the tool and the liquid
- the bases of the nucleic acid polymer strand may be extended such that there is consistent base-to-base spacing of the bases
- the base-to-base spacing may be in a range of 3 A to about 7 A between the bases
- the nucleic acid polymer strand may be extended such that the strands are linear
- an article of manufacture may include a solid planar substrate, and at least one elongated nucleic acid polymer strand disposed on the planar substrate
- the least one elongated nucleic acid polymer strand may have consistent base-to-base spacing over a length of about 1000 base pairs
- the article of manufacture may further include a film disposed on top of the at least one elongated nucleic acid polymer such that the at least one elongated nucleic acid polymer is sandwiched between the planar substrate and the film
- the film may be composed of a carbon or low Z- element
- the planar substrate may be composed of a material such as PDMS, carbon, boron, lithium, hydrogen, beryllium, aluminum, nitrides, nitride oxides, and combinations thereof
- the base-to-base spacing of the at least one elongated nucleic acid strand may be in a range of 3 A to about 7 A
- the plurality of elongated nucleic acid strand may be substantially parallel to one another
- the plurality of elongated nucleic acid strand may include about 1 x 10 6 nucleic acid strands
- the at least one elongated nucleic acid strand may be stretched to a length of at least about 2 ⁇ m
- the at least one nucleic acid polymer acid strand may be labeled with at least one Z-labeling compound
- the Z-labeling compound may be a high-Z atom labeling compound such as Os-bipy, mercuric acetate, platinum dimethylsulfoxide, or cluster labeling
- a method for sequencing at least 200 contiguous bases of a nucleic acid strand using electron microscopy may include labeling a plurality of nucleic acid strands with at least one Z-labeling compound, binding a single labeled nucleic acid strand from a solution containing a plurality of labeled nucleic acid strands onto a tool, stretching the single labeled nucleic acid strand into space such that the single labeled strand of nucleic acid is suspended between an air/solvent interface and a tip of the tool, attaching the stretched labeled nucleic acid to a substrate, and imaging the labeled nucleic acid strand using electron microscopy
- the method may further include pretreating a solution containing a plurality of nucleic acid strands with bisulfite to convert unmethylated cytosine bases to uracil bases prior to the labeling step
- the method may also include denaturing a plurality of nucleic acid strands to generate single stranded nucleic acids prior to the labeling step
- the denaturing step may be carried out by thermal denaturation or chemical denaturation
- the method may also include depositing a layer of carbon on top of the labeled nucleic acid strand attached to the substrate prior to the imaging step
- the nucleic acid may be high molecular weight DNA
- the stretching step results in consistent base-to-base spacing in the nucleic acid strand
- the base-to-base spacing and the label-to-label spacing may be in a range of about 3 A to about 7 A, and specifically may be 5 A
- the nucleic acid strand may be stretched to a length of at least about 25 ⁇ m Only a subset of bases of the nucleic acid strand are labeled
- the subset of bases may include thymines and cytosines
- the subset of bases may include adenine and guanine
- the tool may be a needle such that a tip of the needle has been functionalized with a first coating that binds to a nucleic acid strand
- the needle may be fabricated from a material such as glass, gold, tungsten, polymethyl methylacrylate (PMMA), polystyrene, PVC 1 and silicon
- the coating may be a compound such as PMMA, polystyrene, PVB, and oligonucleotides
- the needle may be functionalized with a second coating that does not bind to nucleic acids
- the second coating may be a compound such as octanethiol, hexanethiol, nonanethiol, decanethiol and septanethiol
- the tip of the needle may have a diameter that is less than about 200 nm
- the needle may be moved into and out of the solution at a rate in a range of about 1 nanometers/second to about 100 meters/second
- the needle may be moved into the solution at a depth having a range of about 0 nm to about 20 ⁇ m
- the at least one labeling compound may be a high-Z atom labeling compound
- the high-Z atom may be one or more compounds such as Os-bipy, mercuric acetate, and platinum dimethylsulfoxide
- the at least one labeling compound may be a high-Z atom cluster label
- the attaching step may include attaching at least one labeled nucleic acid strand to an imaging substrate by employing shelf threading
- the attaching step may include attaching at least one labeled nucleic acid strand to a support substrate by employing shelf threading followed by transferring the at least one labeled nucleic acid strand on the support substrate to an imaging substrate by employing transfer printing
- the attaching step may include attaching at least one labeled nucleic acid strand to a support substrate by employing gap threading
- the attaching step may include attaching at least one labeled nucleic acid strand to a support substrate by employing gap threading following by transferring the at least one labeled nucleic acid strand on the support substrate to an imaging substrate by employing swipe printing
- a method for the controlled placement of at least one nucleic acid strand onto a substrate may include providing a solution containing a plurality of nucleic acid strands, inserting a tip of a needle into the solution, pulling the tip of the needle out of the solution containing a plurality of nucleic acid strands, where the tip of the needle has been functionalized with a first coating that binds to nucleic acids, stretching the nucleic acid strand into empty space such that the single strand of nucleic acid is suspended between an air/solvent interface and each tip of the needle, and attaching at least one stretched nucleic acid strand to a substrate
- the nucleic acid is high molecular weight DNA
- the needle may be fabricated from a material such as glass, gold, tungsten, PMMA, polystyrene, PVC, and silicon
- the first coating may be a compound such as PMMA, polystyrene, PVB, and oligonucleotides
- the needle may be functionalized with a second coating that does not bind to nucleic acids
- the second coating may be a compound such as octanethiol, hexanethiol, nonanethiol, decanethiol, and septanethiol
- the tip of the needle may have a radius of curvature that is less than about 200 nm
- the tip of the needle may be moved into and pulled out of the solution at a rate of about 1 nm/s to about 100 m/s
- the tip of the needle may be moved into the solution at a depth having a range of about 10 nm to about 20 ⁇ m
- the needle may be placed on a single nanopositioner-d ⁇ ven support A plurality of needles may be inserted into the solution simultaneously with the nanopositioner driven support
- the stretching step may result in consistent base-to-base spacing in the nucleic acid strand
- the base-to-base spacing may be in a range of about 3 A to about 7 A
- the base-to-base spacing and the label-to-label spacing may be about 5 A
- the nucleic acid may be stretched to a length of about 100 ⁇ m
- the at least two nucleic acid strands attached to the substrate are oriented substantially parallel to each other
- the attaching step may include employing shelf threading to attach the at least one nucleic acid strand to the substrate
- the attaching step may include using gap threading to attach the at least one nucleic acid strand to the substrate
- the substrate may be an imaging substrate
- the substrate in said attaching step may be a support substrate
- a method for analyzing a nucleic acid sequence stored in a memory where the sequence was determined by labeling a plurality of nucleic acid strands with at least one labeling compound, binding a single labeled nucleic acid strand from a solution containing a plurality of labeled nucleic acid strands onto a tool stretching the single labeled nucleic acid strand into space such that the single labeled strand of nucleic acid is suspended between an air/solvent interface and a tip of the tool, attaching the stretched labeled nucleic acid to a substrate, and imaging the labeled nucleic acid strand using electron microscopy
- the nucleic acid sequence is a genomic sequence of a human subject
- the analyzing may include determining at least one of the presence or absence of one or more single nucleotide polymorphisms, copy number, variants, indels, rearrangements, or whole genome comparisons
- the memory is a media selected from the group consisting of hard or floppy disks, optical media, compact disc (CD), digital video disc (DVD), semiconductor media, and flash memory
- a needle may include a distal end, a proximal end, and a shaft extending between and in fluid communication with said distal proximal end and said proximal end, where the proximal end includes a tip member having a radius of curvature less than about 200 nm and where the tip member has been functionalized with a compound that binds to the end of a nucleic acid
- the needle may be coated with a second compound that does not have an affinity for binding to a nucleic acid
- the tip member may be functionalized with a compound such as PMMA polystyrene, PVB, silanization, oligonucleotides, telomeres, and restriction site overhangs
- the nucleic acid may be single stranded DNA
- the needle may be composed of a compound such as glass, gold, tungsten, PMMA, polystyrene, PVC, and silicon The needle may be disposed on a single nanopositioner-d ⁇ ven
- FIGURE 1 is a flow chart illustrating a method for sequencing a nucleic acid accurately using electron microscopy according to principles of the invention
- FIGURE 2 is schematic showing a needle functionalize with coating 1 , which is capable of binding to a nucleic acid strand and coating 2 which does not bind to a nucleic acid strand
- FIGURE 3 shows a schematic of the radius of curvature of the sharp needle
- FIGURE 4 is a schematic illustration showing a method according to principles of the invention for extending a nucleic acid strand into empty space
- Panel I shows a tip of the needle and a droplet of solution containing a plurality of nucleic acid strands
- Panel Il show the tip of the needle moving into the droplet of solution containing the nucleic acid strands and binding to a single nucleic acid strand
- Panel III shows the nucleic acid strand being stretched out into empty space
- FIGURE 5 is a schematic showing the maximum dipping depth of the needle tip into the droplet of solution containing the nucleic acid strands (Panel I) and the minimum dipping depth (Panel II)
- FIGURE 6 is a schematic showing the minimum dipping depth of the needle tip into the droplet of solution containing nucleic acid strands
- the expanded view schematically shows a needle tip in a droplet of solution specifically binding to a single nucleic acid strand, which may be in solution or at the atmosphere/solution interface
- FIGURE 7 is a schematic showing the method of shelf threading according to principles of the invention
- Panel I shows the sharp needle dipping into the solution containing the labeled nucleic acid strands
- Panel Il shows the sharp needle withdrawing from the solution and stretching the attached nucleic acid out into empty space
- Panel III show the extended nucleic acid coming into contact with the TEM grid
- Panels IV and V show the sharp needle pulling back to release the nucleic acid from the tip of the sharp needle
- FIGURE 8 is schematic representation of the shelf threading method of the invention
- Panel I shows shelf threading employing a single needle
- Panel Il shows shelf threading employing a plurality of needles
- FIGURE 9 is a schematic showing that the extended nucleic acid strand is oriented normal to the droplet surface
- FIGURE 10 is a schematic illustrating that the nucleic acid extended in empty space is brought substantially into contact along its length with the support substrate when the strand is placed upon it
- FIGURE 11 is a schematic showing elongation of a nucleic acid strand by proximal set down followed by more stretching
- FIGURE 12 is a schematic showing large parallel arrays of closely spaced nucleic acid strands, such as DNA strands that can be formed by repeating the basic programmed piezo-actuator-controlled needle motion order of dipping-in, dipping-out, setting-down, dragging, l ⁇ ft ⁇ ng-up, and translating
- the nucleic acid strands in this figure are not depicted as straight as the strands would be in actual practice
- FIGURE 13 is a schematic showing a failure mode where improper consideration of solution surface/support substrate/needle motion angles will induce uncontrolled contact between the support substrate and the suspended strand prior to needle-substrate contact, which in turn will cause strand breakage through overstretching
- FIGURE 14 is a schematic showing a failure mode where wrongly calibrated solution surface/support substrate/needle motion angles will not allow the strand to be brought substantially in contact with the substrate, leaving a significant portion of it suspended in empty space between the solution surface and the point of needle-substrate contact
- FIGURE 15 is a schematic showing the gap threading method according to principles of the invention
- FIGURE 16 is a schematic illustrating the transfer printing method according to principles of the invention following deposition of the nucleic acids onto the support substrate
- FIGURE 17 is a schematic showing the nucleic acid strands on the substrate embedded in top layer prior to imagining by electron microscopy
- FIGURE 18 is a schematic illustrating a system for sequencing a nucleic acid according to principles of the invention
- FIGURE 19 is a schematic illustrating a hypothetical system for sequencing a nucleic acid according to principles of the invention, a simulated image of a single osmium- labeled molecule of ssDNA generated using principles of the invention
- FIGURE 20 is a schematic illustrating the ambiguity in images inherent in alternative preparation methods
- FIGURE 21 is a illustration showing a simple mode droplet holder
- any numerical values recited herein include all values from the lower value to the upper value in increments of one unit provided that there is a separation of at least two units between any lower value and any higher value
- concentration of a component or value of a process variable such as, for example, size, angle size, pressure, time and the like, is, for example, from 1 to 90, specifically from 20 to 80, more specifically from 30 to 70 it is intended that values such as 15 to 85, 22 to 68, 43 to 51 , 30 to 32, etc are expressly enumerated in this specification
- one unit is considered to be 0 0001 , 0 001 , 0 01 or 0 1 as appropriate
- A is Adenine
- C is Cytosine
- G is Guanine
- T Thymine
- U Uracil
- ssDNA is single stranded DNA
- AFM Atomic Force Microscope
- CCD Charge Coupled Device
- CMOS is Complementary Metal Oxide Semiconductor
- DMSO Dimethyl Sulfoxide
- EDTA is Ethylenediaminetetraacetic acid
- HAADF High Angle Annular Dark Field
- IMPREST is Individual Molecule Placement Rapid Empty Space Threading
- PFGE is pulsed field gel electrophoresis
- Os-bipy is Osmium tetroxide 2,2'-b ⁇ pyr ⁇ d ⁇ ne
- PDMS is Polydimethylsiloxane
- PLD-UHV Pulsed Laser Deposition-Ultra High Vacuum
- PMMA is Polymethyl methylacrylate
- PMT Photo Multiplier Tube
- PVB Polyvinyl butyral
- SEM is Scanning Electron Microscopy
- TE is Tris EDTA
- TEM Transmission Electron Microscopy
- UHV Ultra High Vacuum
- Z refers to the number of protons in the nucleus of an atom, also known as atomic number "High-Z” refers to an atomic number greater than then imaging thin-film, but for practical sequencing means higher than about 30, or preferably higher than about 70, or more preferably higher than about 90
- the spacing "between" bases is generally the distance from center to center, or phosphate to phosphate Bases are consistently spaced when in an electron microscopic image of the strand the order of labeled and unlabeled bases can be determined over a specified length e g , about 50 bases, about 100 bases, about 1000 bases, or about 10,000 bases
- pluricity of strands refers to 2 strands, 5 strands, 10 strands, 100 strands, 1000 strands, and so on
- support substrate refers to any matrix to which the extended and/or stretched nucleic acid polymers can adhere
- imaging substrate refers to the substrate that will be used directly for electron microscopy imaging
- the imaging substrate may be placed into the microscope and, optionally, support the imaging thin-film
- the imaging substrate may include holey or lacey formvar mesh, other polymer meshes, thin silicon nitride films containing holes, and other suitable types of grids
- the imaging substrate is generally thicker than the imaging thin-film but is needed to support the delicate imaging thin-film
- the imaging substrate as used herein may refer to the imaging thin-film and the support structure holding it or only the support substrate See M Hayat, Principles and Techniques of Electron Microscopy Biological Applications 4 th edition, which describes general methods in electron microscopy
- imaging thin-film refers to a thin layer of carbon, boron, lithium, hydrogen, beryllium, aluminum, or other low Z-elements and/or nitrides and oxides thereof, and any combination thereof
- the layer may have a thickness in a range of about 0 2 nm to about 30 nm
- the imaging thin-film may be supported on an imaging substrate or other surface
- nucleic acid includes oligonucleotides and polynucleotides, and to DNA or RNA of genomic, recombinant or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strands, or to any DNA- like or RNA-like material, natural, recombinant, or synthetic in origin
- complementary includes the natural hydrogen bonding of polynucleotides under permissive salt and temperature conditions by base-pairing For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A "
- Complementarity between two single-stranded molecules may be partial, in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules
- the degree of complementarity between nucleic acid strands has significant effects of the efficiency and strength of hybridization between nucleic acid strands
- sample refers to biological material that contains nucleic acids, such as tissue or fluid from a human or animal including, but not limited to, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal and genitourinary tracts, tears, saliva, blood cells, tumors, organs, tissues, as well as samples from plants, fungi, bacteria, pathogens and in vitro cell cultures
- a sample may be obtained from any species that contain nucleic acids, phylogenetically encompassing all viruses, prokaryotes, and eukaryotes
- a sample may also include nucleic acids that have been artificially synthesized using techniques known in the art such as solid-phase synthesis or synthesized in vitro using, for example, PCR
- label generally refers to an atom, molecule, cluster, or material that has a higher atomic number (Z) and/or density and/or differential electron scattering than the imaging thin-film material and unlabeled DNA
- label agent may be a compound of different contrast than the bases of the nucleic acid strand itself and is attached to the nucleic acid strand
- cluster generally refers to chemical structure comprising two or more high-Z atoms, which is attached to a nucleic acid strand either base-selectively or base-specifically
- the invention generally relates to methods, devices and articles of manufacture for determining nucleic acid sequences using electron microscopy by direct inspection of labeled, stretched nucleic acids
- the invention relates to methods including controlled placement of a nucleic acid onto a substrate or support using a tool to pull out single strands of nucleic acid from a solution
- the methods of the invention allow for greater accuracy, lower cost, and longer read lengths than current sequencing technology
- the sequencing methods of the invention allow accurate determination of at least about 20 consecutive nucleic acid bases using electron microscopy, preferably at least about 50 consecutive bases, more preferably at least about 1 ,000 consecutive bases, even more preferably at least about 10,000 consecutive bases, and even more preferably at least about 100,000 consecutive bases and even more preferably at least about 1 ,000,000 bases of a nucleic acid sample
- Consecutive bases in this context refers the order of bases in the DNA starting material that is analyzed
- Methods of the invention may allow for imaging at least about 10,000 bases/second, and preferably at least about 100,000 bases/second, and more preferable at least about 200,000 bases per second
- Methods of the invention may allow for imaging at least about 10,000 bases/second, and preferably at least about 100,000 bases/second, and more preferable at least about 200,000 bases per second
- DNA strands arrayed according to the invention sample may be imaged at a high resolution rate of about 1 ⁇ m 2 per second
- a 1 ⁇ m 2 area containing nucleic acid strands may be imaged in 1 second, correspond to an imaging rate of about 500,000 bases per second
- FIG. 1 is a flow chart illustrating a method for sequencing a nucleic acid accurately using electron microscopy according to principles of the invention This figure is provided for illustration and is not intended to limit the invention
- a nucleic-acid containing sample is obtained from a subject containing a nucleic acid sequence(s) of interest
- step 104 using techniques known to those of skill in the art, the nucleic acid of interest is isolated from the sample
- step 106 specific bases of the isolated nucleic acid are labeled with, for example high-Z atoms to generate a high-Z atom labeled nucleic acid polymer
- step 108 the nucleic acid polymer is stretched into empty space to ensure consistent base to base spacing of nucleotides
- nucleic acid polymers are attached to a support and laid out in a non-overlapping pattern (e g , substantially parallel relative to each other)
- step 1 12 the attached nucleic acid polymers are imaged by electron microscopy to determine the position of label
- the nucleic acid of interest may be isolated using methods well known in the art, with the choice of a specific method depending on the source, nature of nucleic acid, and similar factors
- the nucleic acid of interest may be naturally occurring and/or of genomic origin, not of synthetic or recombinant origin, and may include oligonucleotides or polynucleotides either double stranded or single stranded form
- the nucleic acid strand of interest may be of recombinant or synthetic origin, which may be single stranded or doubled stranded
- the nucleic acid is DNA, and in particular, a very high molecular weight DNA having greater than about 100 kilobases In some embodiments the high molecular weight DNA is at least 300 kilobases in length Methods for isolation of very high molecular weight are known (see e g , Murry and Thompson, 1980, Nucleic Acids Research 10 4321-5, and Kovacic, R , ET
- DNA is isolated from eukaryotic cells embedded in agarose plugs to minimize shearing
- the DNA is separated from other cellular components by PFGE and subsequently electro-eluted from the agarose into TE buffer at a concentration in a range of about 0 01 ng/ ⁇ l to about 0 5 ng/ ⁇ l
- the DNA may be denatured into single stranded form from double stranded form using thermal or chemical denaturation methods known to those of skill in the art See Barnes, W , 91 PNAS 2216-2220 (1994)
- thermal denaturation of double stranded DNA may be carried out by heating the DNA sample to 94 0 C for 2 minutes
- the denaturation step may take place before labeling and may take place before threading the nucleic acid It is desirable to convert dsDNA into ssDNA prior to labeling, if sequencing is carried out using ssDNA, however it is not necessary and dsDNA may be labeled as understood by a
- step 106 specific bases of the nucleic acid are labeled with contrast agents, such as high-Z atoms, for efficient detection by electron microscopy
- the nucleic acid should be associated with electron dense atoms in a manner that is at least partially base specific
- a contrast agent or label that is partially base specific ( ⁇ e , "base selective") will preferentially associate with one or more of the four DNA or RNA bases over the others (e g , stains A strongly, G less strongly, T not at all)
- a contrast agent is completely base specific if it associates essentially with only one base (e g , A) or sequence (e g , a particular dimeric sequence)
- a considerable number of methods for labeling DNA are known and can be used in the invention For example base-specific and/or base selective heavy metal staining protocols are described by Whiting ET AL , 474 BIOCHIMICA ET BIOPHYSICA ACTA 334- 348 (1977), Jelen ET AL , 10 GEN PHYSIOL BlOP
- each nucleic acid base may be exclusively labeled with a different high-Z labeling compound, selected subsets of nucleic acid bases may be labeled with a different high-Z labeling compounds, or selected subsets of nucleic acid bases may be labeled with the same high-Z labeling compound, such as Os-bipy (as described below)
- each DNA base for instance A, G 1 C, and T, is exclusively or preferentially labeled with a different Z-labeling compound
- a large variety of high-Z labeling compounds may be employed in the methodologies of the invention including, but without limitation, compounds that contain Pt, Hg, I 1 Rh, Au, Ir, Ag, Os 1 and the like
- Different bases may be distinguished, for example, based on differences in the high-Z labeling agents or between high-Z agents and unlabelled bases, which should be nearly invisible
- Os-bipy and iodine can be distinguished based on their scattering cross
- the TEM imaging detects numerous non- overlapping DNA stands with consistent base spacing
- the fidelity of labeling is not critical
- one advantage of the methods of the invention is that the nucleic acid can be labeled chemically and that for a given reaction batch, it is not necessary that all target bases in each strand be labeled (for example, it is not necessary that each T in a strand be labeled when T-specific labeling is used)
- Complete label accuracy is not necessary because multiple images of the same strand can be combined to determine the underlying sequence because the number of unlabeled bases between the label bases can be determined
- the batch may be adjusted to contain about 20 genome equivalents of total DNA Assume that the base identity of a specific position in the sequence is T, / e , all twenty molecules contain a T at that position
- sequence information for complementary strands can be derived, which also provides additional statistical support for the validity of a given base determination, / e , high confidence in the positions of T on one molecule and high confidence in the positions of A on the complementary strand go hand- ⁇ n- hand
- a given base determination / e
- the labeled Ts on each strand define A positions on the complementary strand
- nucleic acid bases are labeled in a manner that is at least partially base specific
- a solution containing a plurality of nucleic acid molecules is reacted under conditions that label at least about 70%, sometimes at least about 80% and sometimes at least about 90% to about 100% of one or more specific nucleotide bases (A, T, G or C) and less than 20, preferably less than 10% of at least one nucleotide base
- the solution is reacted under conditions where about 90% to about 100% of T and C are labeled while labelling a small percentage of A and G
- the DNA aliquots may be labeled with Os-bipy using different conditions in order to achieve different base-specific labelling densities
- the DNA of interest is isolated and divided into two solutions, i e , solutions 1 and 2 at a concentration in a range of about 0 01 ng/ ⁇ l to about 1 ng/ ⁇ l in each solution
- Each solution is reacted with Os-bipy using different conditions (as described in further detailed below) in order to achieve different base-specific labelling densities
- selected solutions are subjected to a pre-treatment prior to reacting with Os- bipy such as a bisulfite pre-treatment, as described below and in Example 1 , infra
- Solution 1 is reacted for 20 hours at 26°C with a four-fold molar excess of Osmium tetroxide and of 2,2'-b ⁇ pyr ⁇ d ⁇ ne in TE buffer pH 8 0 with 10O mM Tris and 10 mM EDTA, these conditions label about 100% of T's about 85% of C s, about 7% of G's, and about 0% of A's
- Solution 2 is reacted under the same conditions as Solution 1 except that the reaction only proceeds for 15 minutes and only a 2 5-fold molar excess of Osmium tetroxide and of Os-bipy is used these conditions label about 90% of T s, about 8% of Cs, about 5% of G's, and about 0% of A's
- the invention allows for determination of patterns of cytosine methylation using Os-bipy
- solutions 1 and 2 are treated as was Solution 1
- Solutions 3 and 4 are treated as was Solution 2, above
- Solutions 2 and 4 are first subjected to a bisulfite treatment to convert unmethylated C residues to U
- This allows the pattern of methylation to be determined by comparing sequences from solutions treated with bisulfite to those left untreated See Jelen ET AL 10 Gen PHYSIO AND BIOPHYS 461 -473 (1991 )
- Both methylcytosine and U have labeling efficiencies under different conditions in the reaction with Os-bipy that are distinguishable from labeling efficiencies for the canonical four bases
- cluster labeling may be employed in the methods of the invention
- Cluster labels are label compounds that contain more than a single heavy atom
- Cluster labels may be used in protocols that utilize stretching methods that provide sufficient base to base separation Sufficient separation is necessary in order to obtain sequence data that is not limited by steric hindrance between neighboring attached clusters
- Clusters can be attached to oligomers and then the oligomers are hybridized to DNA through complementary base pairing In this manner, complementary sequences could be localized using electron microscopy
- information can be combined from imaging of separate batches of very short cluster-labeled oligomers (t ⁇ mers and tetramers) hybridized to unknown sequences
- the very short cluster-labeled oligomers may have a length in a range of about 5 to about 20 bases
- Clusters that can directly label unmodified DNA, i e DNA that has the natural composition of bases without unnatural bases containing functional groups that may increase the efficiency of cluster labeling, include the t ⁇ osm
- cluster labels may be employed as contrast agents, known clusters may be attached to nucleic acid polymers in a base-specific or base-selective manner using chemical linkage structures known to bind or modify nucleic acid polymers base-selectively or base-specifically
- This approach to cluster labeling may be referred to as "piggybacking"
- Piggybacking may be carried out in the following manner, for example Mercuric acetate may be used to mecurate cytosine, as described in Dale, R , ET AL , 14 BIOCHEMISTRY 2447-2457 (1975), and a cluster compound that will attach to cytosine may be prepared with a mercuric acetate moiety by acetylating the mercury-bridged triosmium cluster (mu3-eta2-c2-t-Bu)Os3(CO)9(mu-Hg)l which is described in Rosenberg, E , ET AL , 10 ORGANOMETALLICS 203-210(1991 ) As
- the invention provides methods for obtaining sequence information of a nucleic acid polymer by determining the positional sequence of selected bases in a specified region of a nucleic acid (e g , DNA) strand
- sequence information is meant that the position of one or more nucleic acid bases of both labeled and unlabeled bases are known and by positional sequence is meant that the positions of at least one base (e g T) relative to other bases is determined
- the positional sequence within a 25 base region may be described as follows
- the method of the invention provides a method for determining the positional sequence of at least one base in a single nucleic acid strand with at least 70% accuracy, alternatively at least 80% accuracy, and often at least 90% accuracy
- the positional sequence may be determined in a region comprising at least 100 up to one million bases, sometimes 200 to one million bases sometimes 1000 to one million bases, sometimes 10,000 to one million bases
- the positional sequence is determined in a region of at least 200, at least 1000, at least 5000, at least 10 000, at least 100,000 or at least one million bases of a strand
- the positional sequence of at least one base is determined for a region comprising 1000 to 100,000 bases
- the accuracy of the method may
- Positional sequence is one type of sequence information It will be apparent from this disclosure that by comparing positional sequence for individual bases (or combinations of bases) it is possible to obtain more complete sequence information, including the positional sequence of all four bases ( ⁇ e complete sequence) within a region of the strand or genome
- the sequencing method(s) of the invention do not rely on incorporating modified nucleotides into DNA or a nucleic acid strand
- the method is compatible with and may be used with, enzymatically incorporated labels (e g , incorporated during polymerization) it is more often used with naturally occurring DNA strands that isolated and labeled directly (using, for example, labels described above and in the literature)
- the present method allows (but does not require) sequence to be determined for a single stranded DNA rather than a double stranded molecule, thus eliminating ambiguities that may arise with other approaches
- Step 108 individual nucleic acid polymers are stretched into empty to space to ensure consistent base to base spacing within the nucleic acid strand
- individual DNA strands are extended into space (/ e a substantial portion of the length of the strand is not supported by a substrate or suspended in a solution or buffer)
- the suspended DNA essentially free from solution or buffer can then be transferred to an imaging substrate for imaging This process may be referred to as DNA threading, discussed in detail below
- the DNA is suspended using a tool to which an end of a DNA strand is attached
- the tool may be dipped into a solution (typically a droplette) containing a plurality of nucleic acid polymer strands or a single strand, a nucleic acid strand may preferentially bind to the tip of the tool, and as the tool is pulled out of solution, the nucleic acid
- the droplette may have a volume in a range of about 0 5 ⁇ l to about 50 ⁇ l, sometimes a volume in a range of about 1 ⁇ l to about 25 ⁇ l, sometimes a volume in a range of about 1 ⁇ l to about 15 ⁇ l, sometime a volume a volume in a range of about 1 ⁇ l to about 10 ⁇ l, and sometimes a volume in a range of about 1 ⁇ l to about 5 ⁇ l
- At least a portion of the single nucleic acid polymer strand may be suspended in space between the tool and the liquid
- the bases of the nucleic acid polymer strand may be extended such that there is consistent base-to-base spacing of the bases
- the base-to-base spacing may be in a range of 3 A to about 7 A between the bases, and specifically about 5 A
- the nucleic acid polymer strand may be extended such that the strands are linear
- the tool used to extract the DNA molecule into empty space may be any of a variety of devices so long as it can be used to bind a single nucleic acid strand and suspend it into space
- the tool is a sharp needle, a hollow needle, or small ( ⁇ e , less than about 300 nm in diameter) magnetic particle that has an affinity to bind nucleic acids used with a magnetic probe
- the tool is a sharp needle
- the sharp needle may be composed of materials such as glass, gold, tungsten, PMMA, polystyrene, PVC, silicon, or any other suitable substance that may be made into a very sharp needle
- the needle tip can be readily made by techniques known to those of ordinary skill in the art such as using a standard pipette puller, microfabrication (Handbook of Microlithography, Micromachining & Microfabrication, P Rai-Choudhury, SPIE Optiacl Engineering Press, 1997), growth, or molding and casting
- a glass needle can be made by heating the middle of a glass fiber (about the same diameter as a micro-capillary tube) in an ethanol flame and pulling from either end of the fiber
- a standard pipette puller can be used
- the needle 200 may have a proximal end 202 including a tip 206 having a diameter less than about 200 nm, a distal end 204, and
- the tip of the needle may be functionalized by coating with a material that preferentially binds to the end of a nucleic acid, and may include without limitation, PMMA, polystyrene, PVB 1 chemical treatments such as silanization, oligo- or polynucleotides complementary to genomic sequences or restriction site overhangs (the oligomers may possess degenerately pairing bases such as inosine, allowing for greater selective range), aptamers with high affinity to specific sequences or structures, ⁇ treptavidin or other proteins with a high affinity to a molecule such a biotin, or any other suitable material that would specifically attach to the ends of the nucleic acid
- the needle tip may be coated with PMMA by dipping in about 0 5% PMMA solution in acetone, and drying in an acetone saturated atmosphere
- the tip of the needle may be coated with a second coating, to limit the area where the nucleic acid can bind, and may include materials such as octanethiol, nonanethiol, hexadecanethiol, or other linear alkane-thiol chains
- coating 1 binds to the ends of the DNA
- coating 2 does not bind or binds less avidly
- a gold needle tip may be dipped into a solution of polystyrene, and then the polystyrene may be crosslinked just at the very tip in an electron beam
- the un-crosslinked polystyrene may be removed from the rest of the needle by methods known to those skilled in the art such as dipping in acetone or chloroform
- the needle could then be dipped into an octanethiol solution, which will form monolayers on gold but not on the polystyrene
- the ends of the DNA will not
- the sharp tool may be a hollow needle
- hollow micro-needles may be manufactured with techniques known in the art, so that a nucleic acid solution may be pumped through the bore Subsequently, the micro-needles may be touched to either a support substrate with an affinity for nucleic acid ends or to a sharper polymer-coated solid needle in order to thread directly out of the hollow bore
- the hollow micro-needles could serve as both direct threading implements and as channels for precise solution control
- the bore may be fabricated by techniques known in the art that only one strand would enter the bore-length-wise, and assist in controlling nucleic acid thread concentration This is technique using a hollow needle is consistent with pulling DNA out of solution using a sharp tool
- the difference with using the hollow needle is that the surface and shape of the solution happens to be very small and constrained by the walls of the hollow needle
- DNA threading is performed by dipping the sharp functionalized needle into and out of the DNA polymer solution, pulling the DNA strands into empty space as shown in Figure 4
- the needle tip may be moved into and out of solution at a rate in a range of about 1 nm/hr to about 10 m/s, and specifically, at a rate in the range of 1 ⁇ m/s to about 10 mm/s
- the DNA strands pulled out remain normal to the surface of the DNA solution
- Nanopositioners including piezo- actuators, such as those used in AFM may be used to control the position and motion of the needle with sub-angstrom precision (using high quality feedback mechanisms)
- Nanopositioners are known in the art and are described, for example, in U S Patent No 5,903,085 and are commercially available from Piezosystem Jena (Germany) Variables that affect efficient threading of single strands include solution temperature and pH, humidity
- the "dipping in" distance is a variable that may control the amount of DNA that attaches to the needle (Figure 5)
- the needle dipping may be a depth in a range of about 1 A to about 20 ⁇ m into the solution
- shallow dipping is used ( Figure 6) With shallow dipping, the needle is placed into the solution in a very short distance (for example, less than about 1 ⁇ m) amount to limit the surface area of the needle available for strand binding
- a very short distance for example, less than about 1 ⁇ m
- Another variable is the amount of time the needle stays in solution
- the number of nucleic acid molecules that attach to the tip may be regulated by controlling the amount of time the tip is allowed to remain in solution For a given solution, longer needle dwell times will result in more attachments, and shorter times will result in fewer attachments, as a function of the time required for a molecule to diffuse in solution and attach to the needle This time range can vary from less than about 1 ns, to multiple seconds or minutes
- the extended nucleic acid should have a base-to base spacing in a range of about 3 A to about 7 A, and specifically about 5 A
- the spacing of the bases should not be construed to be limited exclusively to this range, as the appropriate spacing of bases will depend on a number of factors such as whether the nucleic acid is stretched further by use of a shelf (described below)
- the forces acting between the air-water interface and the needle tip alone should lead to a base-to base spacing of about 5 A or a force of about 65 pN
- the total length of a particular extended strand in empty space will correspond to the number of bases in the strand times the average base-to-base spacing For example, a strand about 10 million bases long may be stretched to a length of about 5 mm given a 5 A base-to-base spacing
- the nucleic acid strand may be stretched to
- the nucleic acid strand may be removed from solution and suspended between two points by attaching the nucleic acid strand to two points in solution using optical or magnetic beads (Bustamante, C , ET AL 421 (6921 ) NATURE 423-427 (2003)) The strand is then freeze dried and the ice is then sublimed away, leaving a suspended single strand that can then be transferred to an imaging substrate
- individual nucleic acid strands are bound to a single magnetic particle which is then withdrawn from the droplette (e g , using a magnetic probe) to extend the DNA strand into space Attachment to Imaging Substrate
- step 110 once the nucleic acid strands are threaded between the needle and the droplet in empty space and the nucleic acid strand is not surrounded by either solution or buffer, the strands can be placed directly onto a substrate, such as a support substrate or an imaging substrate for imaging by electron microscopy
- a substrate such as a support substrate or an imaging substrate for imaging by electron microscopy
- sleep threading In which extended DNA strand are placed on an imaging substrate or are placed on a support substrate and transferred to an imaging substrate in a separate step See Figure 7
- Gap threading A related approach is referred to as "gap threading" in which DNA strands are suspended across a gap in a support substrate and transferred to an imaging substrate in a separate step See Figure 15
- the strands can be placed in a great many orientations including orientations in two and three dimensions so long as strands do not overlap or cross in the "suspended region" (or do so rarely)
- the most convenient and standard method for EM sample preparation is two dimensional typically with a number of strands positioned parallel to each other See, e g , Figure 8 In this configuration, the ratio of sample to empty or 'non- sample' space can be readily maximized In general, the closer the interstrand spacing the better, as long as the strands are not in such close proximity that they interfere with the visibility and identification of their neighbors
- Sub-nanometer precision positioners are commercially available, and a very convenient configuration is to place the strands in parallel lines ranging from about 2 nm to about 10 nm apart In an other embodiment the strands are positioned radially.
- multiple suspended strands may be placed in a substantially linear orientation Figure 12, shows placement of nucleic acid strands 704, such as DNA on a substrate 1202 by needle 706 from a droplet of solution 702 containing nucleic acid strands 704
- nucleic acid strands 704 such as DNA
- Large parallel arrays of closely spaced nucleic acid strands, such as DNA strands, can be formed by repeating the basic programmed nanopositioner-controlled needle motion order of dipping-in, dipping-out, setting-down, and optionally dragging the needle tip along the support substrate in order to deposit the strand, lifting-up, and translating over a desired distance between strands
- millions of strands may be placed onto one support substrate in this manner, particularly using a large array of parallel needles
- Arrays may contain from about 2 to 10 million substantially linear strands and/or parallel strands with a suspension region of length in a range of about 1 ⁇ m to about 5 mm and spacing in a range of about 1 nm to about 10 nm, resulting in a density in a range of about 1 base/nm 2 to about 1 base/5 nm 2 Arrays may have, for example, more than 5, more than 10, more than 100, more than 1000, or more than 10,000 DNA strands
- the methods of the invention can produce linear (straight) double stranded and single stranded nucleic acid strands
- Linearity can be described in terms of dimensions of an imaginary box that encloses the strand (or linear portion thereof) or more conveniently an imaginary rectangle that encloses a two dimensional projection of the strand (or the strand itself) on a supporting substrate
- the linear portion of the strand is usually at least about 2 ⁇ m in length, more often at least about 5 ⁇ m in length, and even more often at least about 10, 20, 30, 50 or 100 ⁇ m in length
- the linear portion of a strand will be nearly the entire length of the strand
- the rectangle is such that if the smallest possible imaginary rectangle were drawn to enclose the strand or linear portion such that all portions of were inside the rectangle, the rectangle would have a length to width ratio of not less than 100 1 , or preferably at least 160 1 , or preferably at least 200 1 , more preferably at least 500 1 , and even more
- shelf threading may be employed for placing DNA directly onto an imaging substrate See Figure 7, Panels I-V for an illustration
- the imaging substrate may support an imaging thin-film that be composed of a material such as single graphene sheets, ultra-thin films of carbon, beryllium oxide or beryllium nitride, water ice (requiring cryo- electron techniques), and other suitable forms of solid low-Z (electron transparent) solids Since these ultra-thin films are very delicate, they are placed on top of or supported by grid or mesh composed of standard formvar lacey film on a TEM grid, microfabricated holes in SiN membranes (DuraSiN by Protochips, lnc ), or similarly fabricated holey grid
- Figure 7 shows a droplet of solution 702 containing a plurality of labeled nucleic acid strands 704 (only one shown for clarity), a needle 706, a TEM grid 708 on top of a PDMS block 710 As shown in Figure 7, Panel I, the needle 706 is
- the support substrate 710 is placed next to the droplet of nucleic acid polymer solution 702 so that the nucleic acid strand suspended between the droplet and the sharp needle is brought down to contact the support substrate Then a plurality of nucleic acid strands are transferred to an imaging substrate or by "transfer printing," as described below Figure 8, Panel I, schematically illustrates a single needle depositing nucleic acid strands 704 onto a PDMS support substrate 710 and Figure 8, Panel Il schematically illustrates a single needle 706 depositing a plurality of nucleic acid strands 704 onto support film covered, fabricated TEM grid 708, one at a time (shown with the needle in two positions of its motion time-line path)
- the nucleic acid strand is always normal to the surface of the droplet
- the angle of the solution surface relative to the support substrate and the motion of the needle is controlled such that the nucleic acid 704 in empty space is brought substantially into contact along its length with the substrate 708 when the strand is placed upon it (Figure 10)
- the nucleic acid may be elongated after it has been "pulled out" of solution
- Figure 11 Panels I-IV, shows elongation of a nucleic acid by proximal setdown followed by more stretching
- the nucleic acid has exaggerated looseness to illustrate greater stretching by mechanical force than pure meniscus forces
- "A" and "B” can represent cross-sectional views of a support such as two bars in an EM grid (on a micro scale) or two strips of PDMS (on a macro scale)
- A" and "B” can also represent two positions on a planer substrate
- Figures 13 and 14 illustrate that several parameters may be considered in extending and placing the DNA strands
- improper consideration of solution surface/support substrate/needle motion angles will induce uncontrolled contact between the support substrate and the suspended strand prior to needle-substrate contact, which in turn will cause strand breakage through overstretching ( Figure 13, Panel II)
- wrongly calibrated solution surface/support substrate/needle motion angles will not allow the strand to be brought substantially in contact with the substrate, leaving a significant portion of it suspended in empty space between the solution surface and the point of needle-substrate contact (Figure 14)
- gap threading may be employed for placing the nucleic acid strands onto the support substrate Gap threading may be carried out in the following manner, which is illustrated schematically in Figure 15
- Figure 15 shows a block of PDMS 1502 with gap 1504 nucleic acid strands 1506 spanning across gap 1504, and an imaging substrate — in this case an ultra-flat silicon grid covered with a carbon film or other low Z film 1508
- the nucleic acid droplet is placed next to a gap in a small block of PDMS
- the PDMS block will have a length of about 3 mm and a width of about 3 mm
- the nucleic acid is spanned across the gap by a sharp needle threading as described above
- the nucleic acid is spanned across the gap 1504
- the ultra-flat silicon grid 1508 covered with a carbon film, holey gold film, or a continuous film of carbon beryllium, other low z film or imaging thin-film (as defined above) is placed in contact with the nucleic
- DNA strands may be placed on a support substrate and subsequently transferred to the imaging substrate or imaging thin-film
- Transfer printing is known in the filed and is generally described by Nakao, H , ET AL 125 J AM CHEM Soc 7162-7163 (2003) Transfer printing may be employed for placing the nucleic acid strands on a support substrate or an imaging support as shown in Figure 16
- Figure 16 schematically illustrates a block of PDMS 1602 having a length of 3 mm and a width of 3 mm, a droplet 1604 containing nucleic acid 1606, and a needle 1608
- the needle 1608 is dipped into the droplet 1604 and a strand of nucleic acid 1606 binds the tip of needle 1608
- the needle 1608 is pulled out of droplet 1604, stretching the nucleic acid strand out into empty space
- the extended nucleic acid strand 1610 is attached to PDMS block 1602 This process is repeated until a plurality of nucleic
- nucleic acid strands may be placed onto a support substrate and transferred onto another support substrate for storage, transport, or for other purposes
- the imaging thin film may be an imaging substrate, which is a thin film composed of without limitation, carbon, boron, beryllium aluminum, or other low-Z-elements and/or nitrides and oxides thereof or imaging thin-film as previously defined These films may be manufactured by known techniques, such as deposition on a cleaved salt crystal or mica.
- an ultra-thin (about 1 5 nm) carbon film is employed
- the imaging substrate is an ultra-flat silicon TEM grid that is covered with a thin (about 1 5 nm thick) supporting carbon film
- the imaging thin-film may also be placed on a formvar micro-mesh-coated TEM grid or a machined silicon grid with regular or irregular holes or apertures
- At least one elongated nucleic acid polymer strand may be disposed on a planar substrate
- the least one elongated nucleic acid polymer strand may have consistent base-to-base spacing over a length of about 1000 base pairs
- a film may be disposed on top of the at least one elongated nucleic acid polymer such that the at least one elongated nucleic acid polymer is sandwiched between the planar substrate and the film
- the film may be composed of a carbon or low Z-element
- the planar substrate may be composed of a material such as PDMS, carbon, boron lithium, hydrogen, beryllium aluminum nitrides, nitride oxides, and combinations thereof
- the methodology described above is not limited to nucleic acid polymers, but can be used with a wide variety of other long (unbranched) high molecular weight molecules
- other high weight polymers including but not limited to nanotubes (e g , carbon nitrate, boron, boron nitrides, and the like), amino acid chains microtubules, actin filaments, other long linear polymers with repeating units, and other polymers may be threaded onto a suitable tool and attached to a suitable substrate
- the methods may be used with a linear polymer that binds differentially at its end (terminus) to the needle or other binding tool
- the linear molecule may be modified at a terminus or termini so that the end binds preferentially to the tool
- the end of the polymer can be complexed to DNA using techniques known by those of skill in the art, which may then bind preferentially at its end to the tool as described above
- the nucleic acid may be damaged by the electron beam generated by the electron microscope For this reason in some embodiments, once placed on the imaging substrate the labeled nucleic acid strands may be stabilized prior to imaging
- additional carbon or other low-Z-elements or polymers can be placed onto the sample by evaporation, sputtering or direct deposition of a pre-made film Indirect evaporation of carbon or other low-Z material may be accomplished by ultra-fast PLD-UHV of carbon or beryllium
- This additional layer ⁇ e , topcoat
- Figure 17 schematically illustrates a TEM grid 1702 having a holey mesh 1704, a base layer 1706, nucleic acid 1708, and a top layer 1710
- the nucleic acid is stabilized by evaporating a topcoat onto the nucleic acid that is made by pulsed laser deposition in a gas atmosphere that cools depositing atoms, but has the conditions of pressure, target to sample distance, pulse length, pulse frequency, and pulse fluence optimized to give a solid homogenous film embedding the labeled nucleic acid polymers These conditions will cause depositing atoms to have minimum reaction with each other en route to the substrate leading to a denser film fully embedding the labels
- the purpose of a topcoat is to stabilize the label and/or DNA in a manner that allows sequence data to be determined, and prevent motion or damage
- the imaging thin-film must be very thin for good images of single atoms to be taken in the TEM Films that are made by standard techniques often become contaminated after exposure to laboratory air This contamination build up causes the films to become thicker which can prevent imaging of single atoms and clusters Besides thickening the film, contaminates from the air can cause structural instabilities of the film when interacting with the electron beam Rigorous cleanliness and care of the films must be taken to ensure that this buildup does not happen
- all of the steps should preferably be done in a controlled hydrocarbon-free environment (e g , pure nitrogen, argon, or other inert gasses)
- a controlled environment preferably a clean hydrocarbon-free gas but more preferably UHV (10 10 torr) This can include performing threading in a controlled atmosphere environment, placing the DNA stands on the film in UHV, and other cleanliness techniques known
- Contamination from the microscope itself is also a key factor that can limit visibility of single atoms Care must be taken to have a very clean, dry system for imaging This includes having cold traps, multiple ion pumps, turbo pumps, titanium sublimation pumps, sorption pumps, stage heaters, and load locks (Dorothy Hoffman, Handbook of Vacuum Science and Technology)
- Step 112 illustrates and embodiment of the invention, where the labeled nucleic acid on the TEM grid is imaged by electron microscopy
- the invention should not be construed to be limited to a TEM grid at this step and may be any imaging substrate known by those of skill in the art
- any suitable electron microscope may be used (e g a T ⁇ tan-80-300, Nion UltraSTEM, or VG 501 electron microscope) preferably with suitable aberration correctors using HAADF STEM to visualize the position of the labels
- Figure 18 shows a system for analyzing a nucleic acid sequence which may include an electron microscope 2202, a processor module 2204, at least one memory module 2206, an analyzer module 2208, a user interface 2210, and a network interface 2212
- Electron microscope 2202 may be configured to generate an electronic signal representing electron dense regions
- Analyzer module 2208 is configured to analyze the nucleic acid sequence based on the electronic signal generated by electron microscope 2202
- the at least one memory module 2206 is adapted to stored at least one of the electronic signals representative of the nucleic acid sequence generated by the electron microscope and/or analysis
- User interface 2210 is configured to allow the user to interact with the analysis
- the at least one memory module includes separate memories for storing the analysis and for storing the electronic signal representing the nucleic acid sequence
- the analyzer 2208 and the at least on memory module 1806 are remote from the electron microscope and connected to the electron microscope through
- data analysis may be collected from a commercially available system or a custom system as shown in Figure 19
- the system in Figure 19 may include an electronic microscope 1902 (commercially available or a custom microscope), a processor detector 1904, an image recognition computer 1906, at least one memory module 1908, an analyzer module 1910, an user interface 1912 (conceptual view on screen), and an optional network interface (internet or intranet)
- the electron microscope may be configured to generate an electronic signal representing a nucleic acid sequence
- the analyzer module 1910 is configured to analyze the nucleic acid sequence based on the electronic signal generated by electron microscope 1902
- memory is a medium selected from hard or floppy disks, optical media, compact disc (CD), digital versatile disc (DVD), semiconductor media, and flash memory
- the final sequence information is assembled either manually or, preferably, using an image recognition system
- Nucleic acid spacing information is generated from the high data output detector which may be, for example, a CCD detector, CMOS or PMT
- An algorithm is employed to determine from the information received from the high data output CCD detector the spacing of the osmium label, for example, and accordingly, determine the sequence of the specific bases for a given labeling reaction batch
- the information received from the CCD is stored on a memory and analyzed
- the memory may include e g , magnetic media such as conventional hard or floppy disks, optical media such as compact disc (CD), digital versatile disc (DVD), or the like, and/or semiconductor media such as flash memory
- Algorithms (computer programs) for sequence assembly are well known
- Programs that may be used or adapted for use in the invention include for example, DNA Naser and Cap3, which are the most common sequence assembly software programs used in the art such as those disclosed by U S Patent No 6,760 668 entitled "Method for Al
- the initial sequence data e g , positional sequences within various strands
- the initial sequence data can be matched to the known reference sequence to accelerate analysis
- the invention comprises analyzing a nucleic acid sequence (A's, T's G's, and Cs) stored in a memory, wherein said sequence was determined by the methods described hereinabove
- the invention comprises receiving imaging data (e g , the positions of labeled and unlabeled bases), positional sequence (optionally positonal sequence in which at least one base is undetermined) or other sequence information, and processing the data to determine the nucleotide sequence of a nucleic acid sample
- the data are received in electronic form
- the nucleic acid sequence is genomic sequence of a human subject
- the analyzing comprises determining at least one of the presence or absence of one or more single nucleotide polymorphisms, copy number, variants, indels, rearrangements, or whole genome sequences
- FIG. 19 A illustrative image of a single stranded DNA strand with Ts labeled is shown in Figure 19, with a diagram illustrating how the pattern of heavy labels correspond to partial, base-specific sequence information for the area imaged Information combining multiple imagings of the same underlying sequence with different labels and/or reaction conditions allows for highly accurate sequence determination
- Figures 20 illustrates the ambiguity inherent in alternative preparation methods Using the methods of the invention, described above and in the specific examples, below, phasing errors will not be introduced as a missing label will just be "read" as a blank spot
- the DNA of interest is isolated from a sample using techniques known to those of ordinary skill in the art
- the DNA of interest is then divided into four solutions, i e , solutions 1 , 2, 3, and 4
- Each solution is reacted with Os-bipy for different lengths of time and with different concentrations of Os-bipy in order to achieve different base-specific labelling densities
- Solutions 1 and 2 are reacted for 20 hours at 26 degrees Celsius with a four-fold molar excess of Osmium tetroxide and of 2,2'-b ⁇ pyr ⁇ d ⁇ ne in TE buffer pH 8 0 with 100 mM Tris and 10 mM EDTA, these conditions label about 100% of T s, about 85% of Cs, about 7% of G's, and about 0% of A s
- Solutions 3 and 4 are reacted under the same conditions as solutions 1 and 2 except that the reaction only proceeds for 15 minutes, and only a 2 5- fold molar excess of Osmium tetroxide and of 2,2'-b ⁇ py ⁇ d ⁇ ne is used, these conditions label about 90% of T's, about 8% of Cs, about 5% of G's, and about 0% of A's
- Solutions 2 and 4 are first subjected to a bisulfite treatment to convert unmethylated C residues to U Bisulfite protocol
- a sharp needle is made by heating a glass fiber in an ethanol flame and pulling to separate thereby resulting in two sharp needles with a radii of curvature at their ends of less than about 200 nm
- One needle is then coated with PMMA by dipping in a 0 5% solution in acetone and drying in an acetone atmosphere.
- the needle is then glued on to a holding piece or clamped onto an arm of a positioner such as a piezo actuator (e.g., programmable AFM silicon cantilever) to control the position and motion of the needle.
- a positioner such as a piezo actuator (e.g., programmable AFM silicon cantilever) to control the position and motion of the needle.
- the needle is dipped into the DNA polymer solution containing the DNA polymers of interest and then pulled out to extend or "pull out” the DNA strands into empty space from the DNA polymer solution.
- the extended DNA polymer strands should remain perpendicular to the surface of the DNA polymer solution.
- the DNA polymers are attached to an ultra-flat silicon TEM grid that is covered with a thin carbon film having a thickness in a range of about 1.5 nm to about 5 nm.
- the silicon TEM grid is made by evaporating carbon on one side of a silicon piece and then etching the back side ensuring that the carbon film is flat using techniques known to those of ordinary skill in the microfabrication industry.
- the grid is placed next to the droplet of DNA polymer solution so that the DNA polymer strand suspended between the droplet and the sharp needle is allowed to contact the grid before being completely “pulled out” of the DNA polymer solution.
- the DNA polymer extended into the empty space is only brought into contact with the TEM grid when the strand is placed on it. Consideration of the angles of the DNA polymer solution with respect to the grid and the motion of the needle is taken to ensure this. Using this threading technique, thousands to millions of strands can be placed parallel to each other on the TEM grid.
- the DNA polymer solution is pulled away from the spanning position using a pipette tip or micropositioners moving the base that the droplet rests on. About 0.5 nm to about 6 nm of carbon is then evaporated to stabilize the DNA polymer. The spanning is done in a controlled environment chamber to minimize evaporation and dust.
- Imaging is performed in a commercially available Titan 80-300 (FEI Company, Hillsboro, OR) with aberration correctors in Z-contrast STEM mode or other suitable high resolution electron microscope.
- the information from the detector is used to determine the spacing of the osmium labels and accordingly, the sequence of the DNA of interest.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008308457A AU2008308457A1 (en) | 2007-10-04 | 2008-10-06 | Sequencing nucleic acid polymers with electron microscopy |
MX2010003724A MX2010003724A (en) | 2007-10-04 | 2008-10-06 | Sequencing nucleic acid polymers with electron microscopy. |
CN2008801193343A CN101889074A (en) | 2007-10-04 | 2008-10-06 | Sequencing nucleic acid polymers with electron microscopy |
CA2701726A CA2701726A1 (en) | 2007-10-04 | 2008-10-06 | Sequencing nucleic acid polymers with electron microscopy |
EA201000427A EA201000427A1 (en) | 2007-10-04 | 2008-10-06 | SEQUENCYING NUCLEIC ACID POLYMERS USING ELECTRON MICROSCOPY |
US12/681,589 US20100331195A1 (en) | 2007-10-04 | 2008-10-06 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
JP2010528215A JP2010539991A (en) | 2007-10-04 | 2008-10-06 | Sequencing of nucleic acid polymers using electron microscopy |
EP08835273A EP2203547A4 (en) | 2007-10-04 | 2008-10-06 | Sequencing nucleic acid polymers with electron microscopy |
US12/753,712 US20100267156A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,693 US8153438B2 (en) | 2007-10-04 | 2010-04-02 | Sequencing nucleic acid polymers with electron microscopy |
US12/753,702 US20100267154A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,708 US20100267155A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,696 US20100267153A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,722 US20100268478A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,717 US20100267157A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
IL204866A IL204866A0 (en) | 2007-10-04 | 2010-04-06 | Sequencing nucleic acid polymers with electron microscopy |
ZA2010/02881A ZA201002881B (en) | 2007-10-04 | 2010-04-23 | Sequencing nucleic acid polymers with electron microscopy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99742707P | 2007-10-04 | 2007-10-04 | |
US60/997,427 | 2007-10-04 | ||
US13296008P | 2008-06-23 | 2008-06-23 | |
US61/132,960 | 2008-06-23 |
Related Child Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/753,712 Continuation US20100267156A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,708 Continuation US20100267155A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,717 Continuation US20100267157A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,722 Continuation US20100268478A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,693 Continuation US8153438B2 (en) | 2007-10-04 | 2010-04-02 | Sequencing nucleic acid polymers with electron microscopy |
US12/753,696 Continuation US20100267153A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
US12/753,702 Continuation US20100267154A1 (en) | 2007-10-04 | 2010-04-02 | Sequencing Nucleic Acid Polymers with Electron Microscopy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009046445A1 true WO2009046445A1 (en) | 2009-04-09 |
Family
ID=40526732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/078986 WO2009046445A1 (en) | 2007-10-04 | 2008-10-06 | Sequencing nucleic acid polymers with electron microscopy |
Country Status (12)
Country | Link |
---|---|
US (8) | US20100331195A1 (en) |
EP (1) | EP2203547A4 (en) |
JP (1) | JP2010539991A (en) |
KR (1) | KR20100089060A (en) |
CN (1) | CN101889074A (en) |
AU (1) | AU2008308457A1 (en) |
CA (1) | CA2701726A1 (en) |
EA (1) | EA201000427A1 (en) |
IL (1) | IL204866A0 (en) |
MX (1) | MX2010003724A (en) |
WO (1) | WO2009046445A1 (en) |
ZA (1) | ZA201002881B (en) |
Cited By (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011091063A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Partition defined detection methods |
WO2011090558A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Simultaneous determination of aneuploidy and fetal fraction |
WO2011091046A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
WO2011090556A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acid in maternal samples |
WO2011100434A2 (en) | 2010-02-10 | 2011-08-18 | Chistopher Su-Yan Own | Aberration-correcting dark-field electron microscopy |
WO2012135730A2 (en) | 2011-03-30 | 2012-10-04 | Verinata Health, Inc. | Method for verifying bioassay samples |
WO2012141712A1 (en) | 2011-04-14 | 2012-10-18 | Verinata Health, Inc. | Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies |
WO2012142334A2 (en) | 2011-04-12 | 2012-10-18 | Verinata Health, Inc. | Resolving genome fractions using polymorphism counts |
WO2013015793A1 (en) | 2011-07-26 | 2013-01-31 | Verinata Health, Inc. | Method for determining the presence or absence of different aneuploidies in a sample |
WO2013016524A1 (en) * | 2011-07-26 | 2013-01-31 | Opgen, Inc. | Methods of elongating nucleic acids |
WO2013052913A2 (en) | 2011-10-06 | 2013-04-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2013052907A2 (en) | 2011-10-06 | 2013-04-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2013055817A1 (en) | 2011-10-11 | 2013-04-18 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2013073610A1 (en) * | 2011-11-15 | 2013-05-23 | ナガヤマ アイピー ホールディングス エルエルシー | Nucleotide sequencing apparatus |
WO2013109981A1 (en) | 2012-01-20 | 2013-07-25 | Sequenom, Inc. | Diagnostic processes that factor experimental conditions |
WO2013184754A2 (en) | 2012-06-05 | 2013-12-12 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using dna origami probes |
WO2013192562A1 (en) | 2012-06-22 | 2013-12-27 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014011928A1 (en) | 2012-07-13 | 2014-01-16 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
WO2014014498A1 (en) | 2012-07-20 | 2014-01-23 | Verinata Health, Inc. | Detecting and classifying copy number variation in a fetal genome |
US8688388B2 (en) | 2011-10-11 | 2014-04-01 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014055774A1 (en) | 2012-10-04 | 2014-04-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014055790A2 (en) | 2012-10-04 | 2014-04-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US20140121132A1 (en) * | 2011-03-11 | 2014-05-01 | Cornell University | Systems and methods for high resolution biomolecular imaging and analysis |
WO2014116598A2 (en) | 2013-01-25 | 2014-07-31 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014120819A1 (en) | 2013-01-31 | 2014-08-07 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules with interacting components |
WO2014164838A1 (en) | 2013-03-12 | 2014-10-09 | Sequenom, Inc. | Quantification of cell-specific nucleic acid markers having a particular methylation state |
WO2014168711A1 (en) | 2013-03-13 | 2014-10-16 | Sequenom, Inc. | Primers for dna methylation analysis |
WO2014182726A2 (en) | 2013-05-07 | 2014-11-13 | Sequenom, Inc. | Genetic markers for macular degeneration disorder treatment |
WO2014204991A1 (en) | 2013-06-17 | 2014-12-24 | Verinata Health, Inc. | Method for determining copy number variations in sex chromosomes |
US20150011425A1 (en) * | 2012-01-27 | 2015-01-08 | Cornell University | Methods and arrays for controlled manipulation of dna and chromatin fragments for genetic and epigenetic analysis |
US8962247B2 (en) | 2008-09-16 | 2015-02-24 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
WO2015061359A1 (en) | 2013-10-21 | 2015-04-30 | Verinata Health, Inc. | Method for improving the sensitivity of detection in determining copy number variations |
WO2015109234A1 (en) | 2014-01-16 | 2015-07-23 | Illumina, Inc. | Gene expression panel for prognosis of prostate cancer recurrence |
WO2015184404A1 (en) | 2014-05-30 | 2015-12-03 | Verinata Health, Inc. | Detecting fetal sub-chromosomal aneuploidies and copy number variations |
WO2016011414A1 (en) | 2014-07-18 | 2016-01-21 | Illumina, Inc. | Non-invasive prenatal diagnosis of fetal genetic condition using cellular dna and cell free dna |
US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US9305756B2 (en) | 2013-03-13 | 2016-04-05 | Agena Bioscience, Inc. | Preparation enhancements and methods of use for MALDI mass spectrometry |
US9310378B2 (en) | 2008-01-15 | 2016-04-12 | Agena Bioscience, Inc. | Compositions and processes for improved mass spectrometry analysis |
WO2016055380A1 (en) | 2014-10-09 | 2016-04-14 | Roche Diagnostics Gmbh | Mutations in the epidermal growth factor receptor kinase domain |
US9323888B2 (en) | 2010-01-19 | 2016-04-26 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US9367663B2 (en) | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2016094853A1 (en) | 2014-12-12 | 2016-06-16 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
US9411937B2 (en) | 2011-04-15 | 2016-08-09 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US9605313B2 (en) | 2012-03-02 | 2017-03-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3202915A1 (en) | 2016-02-03 | 2017-08-09 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
US9926593B2 (en) | 2009-12-22 | 2018-03-27 | Sequenom, Inc. | Processes and kits for identifying aneuploidy |
US9984198B2 (en) | 2011-10-06 | 2018-05-29 | Sequenom, Inc. | Reducing sequence read count error in assessment of complex genetic variations |
US10072283B2 (en) | 2010-09-24 | 2018-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target DNA using immobilized primers |
WO2018195483A1 (en) | 2017-04-21 | 2018-10-25 | Illuminia, Inc. | Using cell-free dna fragment size to detect tumor-associated variant |
EP3409791A1 (en) | 2013-03-15 | 2018-12-05 | Verinata Health, Inc | Generating cell-free dna libraries directly from blood |
EP3418929A1 (en) | 2013-09-27 | 2018-12-26 | Codexis, Inc. | Automated screening of enzyme variants |
WO2018236827A1 (en) | 2017-06-20 | 2018-12-27 | Illumina, Inc. | Methods for accurate computational decomposition of dna mixtures from contributors of unknown genotypes |
WO2018236911A1 (en) | 2017-06-20 | 2018-12-27 | Illumina, Inc. | Methods and systems for decomposition and quantification of dna mixtures from multiple contributors of known or unknown genotypes |
US10196681B2 (en) | 2011-10-06 | 2019-02-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2019109086A1 (en) | 2017-12-01 | 2019-06-06 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
US10424394B2 (en) | 2011-10-06 | 2019-09-24 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10622094B2 (en) | 2013-06-21 | 2020-04-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10699800B2 (en) | 2013-05-24 | 2020-06-30 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10738358B2 (en) | 2008-09-16 | 2020-08-11 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US10774375B2 (en) | 2015-09-18 | 2020-09-15 | Agena Bioscience, Inc. | Methods and compositions for the quantitation of mitochondrial nucleic acid |
US10930368B2 (en) | 2013-04-03 | 2021-02-23 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10964409B2 (en) | 2013-10-04 | 2021-03-30 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11004537B2 (en) | 2011-06-24 | 2021-05-11 | Sequenom, Inc. | Methods and processes for non invasive assessment of a genetic variation |
US11200963B2 (en) | 2016-07-27 | 2021-12-14 | Sequenom, Inc. | Genetic copy number alteration classifications |
US11332774B2 (en) | 2010-10-26 | 2022-05-17 | Verinata Health, Inc. | Method for determining copy number variations |
US11365447B2 (en) | 2014-03-13 | 2022-06-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2022164968A1 (en) | 2021-01-29 | 2022-08-04 | Day Zero Diagnostics, Inc. | Methods for enriching microorganisms from low abundance clinical samples for dna sequencing |
US11694768B2 (en) | 2017-01-24 | 2023-07-04 | Sequenom, Inc. | Methods and processes for assessment of genetic variations |
US11783911B2 (en) | 2014-07-30 | 2023-10-10 | Sequenom, Inc | Methods and processes for non-invasive assessment of genetic variations |
US11789906B2 (en) | 2014-11-19 | 2023-10-17 | Arc Bio, Llc | Systems and methods for genomic manipulations and analysis |
US11929146B2 (en) | 2013-10-07 | 2024-03-12 | Sequenom, Inc. | Systems for non-invasive assessment of chromosome alterations using changes in subsequence mappability |
US11929149B2 (en) | 2015-08-06 | 2024-03-12 | Arc Bio, Llc | Systems and methods for genomic analysis |
US11965211B2 (en) | 2008-09-05 | 2024-04-23 | Aqtual, Inc. | Methods for sequencing samples |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8021841B1 (en) * | 2007-07-11 | 2011-09-20 | Kenneth David Schatz | Methods and apparatuses for spatially separating molecules attached to a support and uses in biotechnology |
WO2012064850A1 (en) * | 2010-11-09 | 2012-05-18 | Michael Andregg | Liquid-gas interface mediated molecule manipulation |
EP3604555A1 (en) | 2011-10-14 | 2020-02-05 | President and Fellows of Harvard College | Sequencing by structure assembly |
EP2771102B1 (en) * | 2011-10-25 | 2023-06-21 | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University | Programmable arrays |
JP2014176297A (en) * | 2011-11-11 | 2014-09-25 | Nagayama Ip Holdings Llc | Base-supporting labeling method, base sequence information acquisition method, and base-supporting labeled single-stranded nucleic acid |
EP4108782B1 (en) | 2011-12-22 | 2023-06-07 | President and Fellows of Harvard College | Compositions and methods for analyte detection |
US11021737B2 (en) | 2011-12-22 | 2021-06-01 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US8858778B2 (en) * | 2012-01-19 | 2014-10-14 | Michael James Darling | Method for DNA defined etching of a graphene nanostructure |
EP2971184B1 (en) | 2013-03-12 | 2019-04-17 | President and Fellows of Harvard College | Method of generating a three-dimensional nucleic acid containing matrix |
EP3003392B1 (en) | 2013-06-04 | 2019-10-23 | President and Fellows of Harvard College | Rna-guideded transcriptional regulation |
CN106460032B (en) | 2013-12-05 | 2019-12-24 | 生捷科技控股公司 | Preparation of patterned arrays |
EP3077430A4 (en) | 2013-12-05 | 2017-08-16 | Centrillion Technology Holdings Corporation | Modified surfaces |
EP3077545B1 (en) | 2013-12-05 | 2020-09-16 | Centrillion Technology Holdings Corporation | Methods for sequencing nucleic acids |
US11060139B2 (en) | 2014-03-28 | 2021-07-13 | Centrillion Technology Holdings Corporation | Methods for sequencing nucleic acids |
WO2016007839A1 (en) | 2014-07-11 | 2016-01-14 | President And Fellows Of Harvard College | Methods for high-throughput labelling and detection of biological features in situ using microscopy |
US20160032281A1 (en) * | 2014-07-31 | 2016-02-04 | Fei Company | Functionalized grids for locating and imaging biological specimens and methods of using the same |
CN104630346A (en) * | 2015-01-05 | 2015-05-20 | 东南大学 | Sequencing method of single DNA molecule based on high-resolution transmission electron microscopy |
AU2016349288A1 (en) | 2015-11-03 | 2018-05-31 | President And Fellows Of Harvard College | Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix |
US9989482B2 (en) * | 2016-02-16 | 2018-06-05 | General Electric Company | Methods for radiographic and CT inspection of additively manufactured workpieces |
CN116200465A (en) | 2016-04-25 | 2023-06-02 | 哈佛学院董事及会员团体 | Hybrid chain reaction method for in situ molecular detection |
WO2018045186A1 (en) | 2016-08-31 | 2018-03-08 | President And Fellows Of Harvard College | Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing |
CN118389650A (en) | 2016-08-31 | 2024-07-26 | 哈佛学院董事及会员团体 | Method for generating a library of nucleic acid sequences for detection by fluorescence in situ sequencing |
CN110225980B (en) | 2016-11-21 | 2023-01-06 | 纳米线科技公司 | Chemical compositions and methods of use thereof |
JP7024490B2 (en) * | 2017-02-27 | 2022-02-24 | 住友金属鉱山株式会社 | Contaminated deposit quantification method and sample analysis method |
CN109789167A (en) | 2017-04-14 | 2019-05-21 | 哈佛学院董事及会员团体 | Method for generating cell-derived microfilament network |
CN112703255A (en) | 2018-05-14 | 2021-04-23 | 纳米线科技公司 | Chemical compositions and methods of use thereof |
SG11202101934SA (en) | 2018-07-30 | 2021-03-30 | Readcoor Llc | Methods and systems for sample processing or analysis |
WO2020076976A1 (en) | 2018-10-10 | 2020-04-16 | Readcoor, Inc. | Three-dimensional spatial molecular indexing |
CN111324096B (en) * | 2020-03-03 | 2021-04-23 | 郑州旭飞光电科技有限公司 | Traceability system and traceability method for processing and packaging information of substrate glass |
CN111537529A (en) * | 2020-04-09 | 2020-08-14 | 中国科学院微电子研究所 | Silicon mesh for attaching transmission electron microscope sample and preparation method thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789161A (en) * | 1990-09-20 | 1998-08-04 | Amoco Corporation | Methods for genome identification using direct label probe composition |
US5903085A (en) * | 1997-06-18 | 1999-05-11 | Phase Metrics, Inc. | Piezoelectric nanopositioner |
US20040248144A1 (en) * | 2001-03-16 | 2004-12-09 | Kalim Mir | Arrays and methods of use |
US20060003437A1 (en) * | 2002-06-26 | 2006-01-05 | Fujitsu Limited | Target detecting device and target capturer, device and method for molecular adsorption or desorption, and device and method for protein detection |
US20060060778A1 (en) * | 2004-09-03 | 2006-03-23 | Masamichi Fujihira | Probe microscope system suitable for observing sample of long body |
US20060204965A1 (en) * | 2003-04-21 | 2006-09-14 | Higuchi Russell G | Associations of polymorphisms in the frbz gene in obesity and osteoporosis |
US20070054306A1 (en) * | 1996-05-29 | 2007-03-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US20070134699A1 (en) * | 2005-11-09 | 2007-06-14 | Zs Genetics, Inc. | Nano-scale ligand arrays on substrates for particle beam instruments and related methods |
US20070172869A1 (en) * | 2000-12-01 | 2007-07-26 | Hardin Susan H | Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis |
US20070190326A1 (en) * | 2000-12-15 | 2007-08-16 | The Arizona Board Of Regents | Method for patterning metal using nanoparticle containing precursors |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4689295A (en) * | 1983-01-20 | 1987-08-25 | Integrated Genetics, Inc. | Test for Salmonella |
US6221581B1 (en) * | 1984-04-27 | 2001-04-24 | Enzo Diagnostics, Inc. | Processes for detecting polynucleotides, determining genetic mutations or defects in genetic material, separating or isolating nucleic acid of interest from samples, and useful compositions of matter and multihybrid complex compositions |
US5447841A (en) * | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
US6150089A (en) | 1988-09-15 | 2000-11-21 | New York University | Method and characterizing polymer molecules or the like |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5106729A (en) | 1989-07-24 | 1992-04-21 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Method for visualizing the base sequence of nucleic acid polymers |
JPH05244997A (en) * | 1992-03-04 | 1993-09-24 | Hitachi Ltd | Method for determining base sequence of dna or rna |
US5871912A (en) * | 1992-04-30 | 1999-02-16 | Institut Pasteur | Nucleic acid probes, sequences and methods for detecting mycobacterium tuberculosis resistant to isoniazid |
US5472881A (en) * | 1992-11-12 | 1995-12-05 | University Of Utah Research Foundation | Thiol labeling of DNA for attachment to gold surfaces |
CA2155186A1 (en) * | 1993-02-01 | 1994-08-18 | Kevin M. Ulmer | Methods and apparatus for dna sequencing |
GB9401200D0 (en) * | 1994-01-21 | 1994-03-16 | Medical Res Council | Sequencing of nucleic acids |
US20020168642A1 (en) * | 1994-06-06 | 2002-11-14 | Andrzej Drukier | Sequencing duplex DNA by mass spectroscopy |
EP0782633A4 (en) * | 1994-09-23 | 2002-01-02 | Sydney D Finkelstein | Topographic genotyping |
US5601982A (en) * | 1995-02-07 | 1997-02-11 | Sargent; Jeannine P. | Method and apparatus for determining the sequence of polynucleotides |
US5843650A (en) * | 1995-05-01 | 1998-12-01 | Segev; David | Nucleic acid detection and amplification by chemical linkage of oligonucleotides |
US6852487B1 (en) * | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US6582921B2 (en) | 1996-07-29 | 2003-06-24 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses thereof |
GB9620209D0 (en) * | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
US6136543A (en) * | 1997-01-31 | 2000-10-24 | Hitachi, Ltd. | Method for determining nucleic acids base sequence and apparatus therefor |
CA2205081A1 (en) * | 1997-06-04 | 1998-12-04 | Graham Dellaire | A method to map and isolate regions of chromosomes that interact or associate functionally within or between chromosomes in vivo |
DE19900511C2 (en) * | 1999-01-08 | 2001-03-15 | Deutsches Krebsforsch | Molecular biological markers for analytical electron microscopy |
WO2000075868A2 (en) * | 1999-06-07 | 2000-12-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for use in three-dimensional structural determination |
DE19937512B4 (en) * | 1999-08-09 | 2006-08-24 | Alexander Cherkasky | Method and apparatus for rapid genome sequencing by linearization or separation of the DNA |
US7244559B2 (en) * | 1999-09-16 | 2007-07-17 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
US7211390B2 (en) | 1999-09-16 | 2007-05-01 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
WO2001079548A2 (en) * | 2000-04-14 | 2001-10-25 | Cornell Research Foundation, Inc. | Method of designing addressable array for detection of nucleic acid sequence differences using ligase detection reaction |
JP2002153271A (en) * | 2000-11-17 | 2002-05-28 | Jeol Ltd | Method for determining base sequence of dna or rna and dna sequencer |
US7419833B2 (en) * | 2000-11-17 | 2008-09-02 | Nagayama Ip Holdings Llc | Method for nucleic acid sequencing |
US20020182626A1 (en) * | 2001-03-16 | 2002-12-05 | Daniel Tuse | Episomal non-transforming nucleic acid elements in functional genomic and antigenic applications |
FR2823223B1 (en) | 2001-04-04 | 2004-03-12 | Centre Nat Rech Scient | SUPPORTED BILAYER STRUCTURE FOR PRESENTING A NUCLEIC ACID ASSOCIATED WITH A PROTEIN |
GB0112238D0 (en) * | 2001-05-18 | 2001-07-11 | Medical Biosystems Ltd | Sequencing method |
GB2378245A (en) * | 2001-08-03 | 2003-02-05 | Mats Nilsson | Nucleic acid amplification method |
AU2002332846A1 (en) * | 2001-09-07 | 2003-04-07 | Boston University | Lanthanide binding tags |
FR2829580B1 (en) * | 2001-09-07 | 2004-02-13 | Bio Merieux | HYBRID OR COMPLEX READING, DETECTION OR QUANTIFICATION METHOD USED IN THIS METHOD AND BIOPUCE USING THE SAME |
US20040086885A1 (en) * | 2002-02-22 | 2004-05-06 | Purdue Research Foundation | Magnetic nanomaterials and methods for detection of biological materials |
JP4120240B2 (en) * | 2002-03-06 | 2008-07-16 | 株式会社島津製作所 | Biological foreign body inspection method |
US20040081985A1 (en) * | 2002-07-12 | 2004-04-29 | Affymetrix, Inc. | Systems and method for examination of microarrays using scanning electron microscope |
US20050009055A1 (en) * | 2002-07-12 | 2005-01-13 | Affymetrix, Inc. | System and method for examination of microarrays using scanning electron microscope |
AU2003267583A1 (en) * | 2002-09-19 | 2004-04-08 | The Chancellor, Master And Scholars Of The University Of Oxford | Molecular arrays and single molecule detection |
EP1424671A1 (en) * | 2002-11-29 | 2004-06-02 | Alrec Sign & Display B.V. | Illuminated sign |
JP2004212355A (en) * | 2003-01-09 | 2004-07-29 | Hitachi Ltd | Biological electron microscope and method of sample observation |
US7745116B2 (en) * | 2003-04-08 | 2010-06-29 | Pacific Biosciences Of California, Inc. | Composition and method for nucleic acid sequencing |
US20100035254A1 (en) | 2003-04-08 | 2010-02-11 | Pacific Biosciences Of California, Inc. | Composition and method for nucleic acid sequencing |
US7625346B2 (en) * | 2003-05-30 | 2009-12-01 | Boston Scientific Scimed, Inc. | Transbronchial needle aspiration device |
US20070072187A1 (en) | 2003-11-28 | 2007-03-29 | Blok Herman J | Novel methods and apparatus for cell based microarray assays |
US20050147977A1 (en) * | 2003-12-29 | 2005-07-07 | Tae-Woong Koo | Methods and compositions for nucleic acid detection and sequence analysis |
US7381529B2 (en) * | 2003-12-31 | 2008-06-03 | Intel Corporation | Methods and compositions for detecting nucleic acids using scanning probe microscopy and nanocodes |
EP1735811B1 (en) | 2004-04-02 | 2015-09-09 | California Institute Of Technology | Method and system for ultrafast photoelectron microscope |
WO2005118877A2 (en) * | 2004-06-02 | 2005-12-15 | Vicus Bioscience, Llc | Producing, cataloging and classifying sequence tags |
BRPI0513308A (en) * | 2004-07-14 | 2008-05-06 | Zs Genetics Inc | systems and methods of analysis of nucleic acid polymers and related components |
US20090239215A1 (en) * | 2004-12-16 | 2009-09-24 | Brandeis University | Clonable Tag for Purification and Electron Microscopy Labeling |
US7875426B2 (en) * | 2005-02-04 | 2011-01-25 | University Of South Florida | DNA biochip and methods of use |
JP2006262834A (en) * | 2005-03-25 | 2006-10-05 | Canon Inc | Method for determining base sequence of nucleic acid and nucleic acid base sequence analyzer based on the method |
US20060287833A1 (en) * | 2005-06-17 | 2006-12-21 | Zohar Yakhini | Method and system for sequencing nucleic acid molecules using sequencing by hybridization and comparison with decoration patterns |
US20090031444A1 (en) * | 2005-09-09 | 2009-01-29 | Peter Egbertus Wittich | Homologous recombination in plants |
CA2627410A1 (en) * | 2005-10-27 | 2007-05-03 | The Trustees Of Boston University | Real time nucleic acid detection in vivo using protein complementation |
US20090018029A1 (en) | 2005-11-16 | 2009-01-15 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
US20070128610A1 (en) * | 2005-12-02 | 2007-06-07 | Buzby Philip R | Sample preparation method and apparatus for nucleic acid sequencing |
WO2007089542A2 (en) * | 2006-01-27 | 2007-08-09 | Zs Genetics, Inc. | Systems and methods of analyzing nucleic acid polymers by using particle beams |
ES2301342B1 (en) * | 2006-03-14 | 2009-05-01 | Oryzon Genomics, S.A. | "METHOD OF ANALYSIS OF NUCLEIC ACIDS". |
DK1840223T3 (en) * | 2006-03-25 | 2010-03-29 | Univ Ruprecht Karls Heidelberg | Method for Microscopic Determination of a Selected Intracellular DNA Section of Known Nucleotide Sequence |
JP5092462B2 (en) * | 2006-06-13 | 2012-12-05 | 株式会社デンソー | Mechanical quantity sensor |
WO2008011430A2 (en) * | 2006-07-17 | 2008-01-24 | Fox Chase Cancer Center | Compositions and methods for the treatment of diseases associated with aberrant cilia assembly and regulation |
WO2008079169A2 (en) * | 2006-07-19 | 2008-07-03 | Bionanomatrix, Inc. | Nanonozzle device arrays: their preparation and use for macromolecular analysis |
WO2008022035A2 (en) * | 2006-08-10 | 2008-02-21 | The Scripps Research Institute | Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal |
US20080060778A1 (en) * | 2006-09-08 | 2008-03-13 | Abraham Velasco-Tellez | Binder composition and method of forming foundry sand cores and molds |
US20090208965A1 (en) * | 2006-10-25 | 2009-08-20 | Ikonisys, Inc. | Automated method for detecting cancers and high grade hyperplasias |
EP2944647A1 (en) | 2007-07-26 | 2015-11-18 | Cellay, Inc. | Highly visible chromosome-specific probes and related methods |
WO2009052214A2 (en) * | 2007-10-15 | 2009-04-23 | Complete Genomics, Inc. | Sequence analysis using decorated nucleic acids |
JP2009178159A (en) * | 2007-11-05 | 2009-08-13 | Hitachi Plant Technologies Ltd | Method of nucleic acid sequence detection and nucleic acid sequence detection substrate |
-
2008
- 2008-10-06 JP JP2010528215A patent/JP2010539991A/en active Pending
- 2008-10-06 EP EP08835273A patent/EP2203547A4/en not_active Withdrawn
- 2008-10-06 AU AU2008308457A patent/AU2008308457A1/en not_active Abandoned
- 2008-10-06 CA CA2701726A patent/CA2701726A1/en not_active Abandoned
- 2008-10-06 CN CN2008801193343A patent/CN101889074A/en active Pending
- 2008-10-06 US US12/681,589 patent/US20100331195A1/en not_active Abandoned
- 2008-10-06 KR KR1020107008686A patent/KR20100089060A/en not_active Application Discontinuation
- 2008-10-06 WO PCT/US2008/078986 patent/WO2009046445A1/en active Application Filing
- 2008-10-06 MX MX2010003724A patent/MX2010003724A/en unknown
- 2008-10-06 EA EA201000427A patent/EA201000427A1/en unknown
-
2010
- 2010-04-02 US US12/753,693 patent/US8153438B2/en not_active Expired - Fee Related
- 2010-04-02 US US12/753,722 patent/US20100268478A1/en not_active Abandoned
- 2010-04-02 US US12/753,712 patent/US20100267156A1/en not_active Abandoned
- 2010-04-02 US US12/753,717 patent/US20100267157A1/en not_active Abandoned
- 2010-04-02 US US12/753,696 patent/US20100267153A1/en not_active Abandoned
- 2010-04-02 US US12/753,708 patent/US20100267155A1/en not_active Abandoned
- 2010-04-02 US US12/753,702 patent/US20100267154A1/en not_active Abandoned
- 2010-04-06 IL IL204866A patent/IL204866A0/en unknown
- 2010-04-23 ZA ZA2010/02881A patent/ZA201002881B/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789161A (en) * | 1990-09-20 | 1998-08-04 | Amoco Corporation | Methods for genome identification using direct label probe composition |
US20070054306A1 (en) * | 1996-05-29 | 2007-03-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US5903085A (en) * | 1997-06-18 | 1999-05-11 | Phase Metrics, Inc. | Piezoelectric nanopositioner |
US20070172869A1 (en) * | 2000-12-01 | 2007-07-26 | Hardin Susan H | Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis |
US20070190326A1 (en) * | 2000-12-15 | 2007-08-16 | The Arizona Board Of Regents | Method for patterning metal using nanoparticle containing precursors |
US20040248144A1 (en) * | 2001-03-16 | 2004-12-09 | Kalim Mir | Arrays and methods of use |
US20060003437A1 (en) * | 2002-06-26 | 2006-01-05 | Fujitsu Limited | Target detecting device and target capturer, device and method for molecular adsorption or desorption, and device and method for protein detection |
US20060204965A1 (en) * | 2003-04-21 | 2006-09-14 | Higuchi Russell G | Associations of polymorphisms in the frbz gene in obesity and osteoporosis |
US20060060778A1 (en) * | 2004-09-03 | 2006-03-23 | Masamichi Fujihira | Probe microscope system suitable for observing sample of long body |
US20070134699A1 (en) * | 2005-11-09 | 2007-06-14 | Zs Genetics, Inc. | Nano-scale ligand arrays on substrates for particle beam instruments and related methods |
Non-Patent Citations (1)
Title |
---|
See also references of EP2203547A4 * |
Cited By (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9873912B2 (en) | 2008-01-15 | 2018-01-23 | Agena Bioscience, Inc. | Compositions and processes for improved mass spectrometry analysis |
US10329612B2 (en) | 2008-01-15 | 2019-06-25 | Agena Bioscience, Inc. | Compositions and processes for improved mass spectrometry analysis |
US9310378B2 (en) | 2008-01-15 | 2016-04-12 | Agena Bioscience, Inc. | Compositions and processes for improved mass spectrometry analysis |
US12077819B2 (en) | 2008-01-15 | 2024-09-03 | Agena Bioscience, Inc. | Compositions and processes for improved mass spectrometry analysis |
US11965211B2 (en) | 2008-09-05 | 2024-04-23 | Aqtual, Inc. | Methods for sequencing samples |
US12018336B2 (en) | 2008-09-05 | 2024-06-25 | Aqtual, Inc. | Methods for sequencing samples |
US8962247B2 (en) | 2008-09-16 | 2015-02-24 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
US10612086B2 (en) | 2008-09-16 | 2020-04-07 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US10738358B2 (en) | 2008-09-16 | 2020-08-11 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US9926593B2 (en) | 2009-12-22 | 2018-03-27 | Sequenom, Inc. | Processes and kits for identifying aneuploidy |
US11180799B2 (en) | 2009-12-22 | 2021-11-23 | Sequenom, Inc. | Processes and kits for identifying aneuploidy |
US10662474B2 (en) | 2010-01-19 | 2020-05-26 | Verinata Health, Inc. | Identification of polymorphic sequences in mixtures of genomic DNA by whole genome sequencing |
US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
US11875899B2 (en) | 2010-01-19 | 2024-01-16 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
US11697846B2 (en) | 2010-01-19 | 2023-07-11 | Verinata Health, Inc. | Detecting and classifying copy number variation |
EP4074838A1 (en) | 2010-01-19 | 2022-10-19 | Verinata Health, Inc. | Novel protocol for preparing sequencing libraries |
US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US11286520B2 (en) | 2010-01-19 | 2022-03-29 | Verinata Health, Inc. | Method for determining copy number variations |
EP4450645A2 (en) | 2010-01-19 | 2024-10-23 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic in maternal samples |
EP3878973A1 (en) | 2010-01-19 | 2021-09-15 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic in maternal samples |
US10941442B2 (en) | 2010-01-19 | 2021-03-09 | Verinata Health, Inc. | Sequencing methods and compositions for prenatal diagnoses |
EP3006573A1 (en) | 2010-01-19 | 2016-04-13 | Verinata Health, Inc | Methods for determining fraction of fetal nucleic acids in maternal samples |
US9323888B2 (en) | 2010-01-19 | 2016-04-26 | Verinata Health, Inc. | Detecting and classifying copy number variation |
WO2011090556A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acid in maternal samples |
US10586610B2 (en) | 2010-01-19 | 2020-03-10 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US10482993B2 (en) | 2010-01-19 | 2019-11-19 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
US9657342B2 (en) | 2010-01-19 | 2017-05-23 | Verinata Health, Inc. | Sequencing methods for prenatal diagnoses |
US10415089B2 (en) | 2010-01-19 | 2019-09-17 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US11884975B2 (en) | 2010-01-19 | 2024-01-30 | Verinata Health, Inc. | Sequencing methods and compositions for prenatal diagnoses |
WO2011091046A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
EP3492601A1 (en) | 2010-01-19 | 2019-06-05 | Verinata Health, Inc | Novel protocol for preparing sequencing libraries |
WO2011091063A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Partition defined detection methods |
EP3382037A1 (en) | 2010-01-19 | 2018-10-03 | Verinata Health, Inc | Methods for determining fraction of fetal nucleic acids in maternal samples |
EP2883965A1 (en) | 2010-01-19 | 2015-06-17 | Verinata Health, Inc | Method for determining copy number variations |
WO2011090559A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Sequencing methods and compositions for prenatal diagnoses |
WO2011090557A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Method for determining copy number variations |
EP2848703A1 (en) | 2010-01-19 | 2015-03-18 | Verinata Health, Inc | Simultaneous determination of aneuploidy and fetal fraction |
WO2011090558A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Simultaneous determination of aneuploidy and fetal fraction |
EP3260555A1 (en) | 2010-01-19 | 2017-12-27 | Verinata Health, Inc | Novel protocol for preparing sequencing libraries |
WO2011100434A2 (en) | 2010-02-10 | 2011-08-18 | Chistopher Su-Yan Own | Aberration-correcting dark-field electron microscopy |
US10072283B2 (en) | 2010-09-24 | 2018-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target DNA using immobilized primers |
US11332774B2 (en) | 2010-10-26 | 2022-05-17 | Verinata Health, Inc. | Method for determining copy number variations |
US20140121132A1 (en) * | 2011-03-11 | 2014-05-01 | Cornell University | Systems and methods for high resolution biomolecular imaging and analysis |
WO2012135730A2 (en) | 2011-03-30 | 2012-10-04 | Verinata Health, Inc. | Method for verifying bioassay samples |
EP3456844A1 (en) | 2011-04-12 | 2019-03-20 | Verinata Health, Inc | Resolving genome fractions using polymorphism counts |
US10658070B2 (en) | 2011-04-12 | 2020-05-19 | Verinata Health, Inc. | Resolving genome fractions using polymorphism counts |
WO2012142334A2 (en) | 2011-04-12 | 2012-10-18 | Verinata Health, Inc. | Resolving genome fractions using polymorphism counts |
EP3567124A1 (en) | 2011-04-12 | 2019-11-13 | Verinata Health, Inc. | Resolving genome fractions using polymorphism counts |
EP4039820A1 (en) | 2011-04-12 | 2022-08-10 | Verinata Health, Inc. | Resolving genome fractions using polymorphism counts |
US9447453B2 (en) | 2011-04-12 | 2016-09-20 | Verinata Health, Inc. | Resolving genome fractions using polymorphism counts |
EP3078752A1 (en) | 2011-04-12 | 2016-10-12 | Verinata Health, Inc | Resolving genome fractions using polymorphism counts |
WO2012141712A1 (en) | 2011-04-14 | 2012-10-18 | Verinata Health, Inc. | Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies |
US9411937B2 (en) | 2011-04-15 | 2016-08-09 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US11004537B2 (en) | 2011-06-24 | 2021-05-11 | Sequenom, Inc. | Methods and processes for non invasive assessment of a genetic variation |
WO2013015793A1 (en) | 2011-07-26 | 2013-01-31 | Verinata Health, Inc. | Method for determining the presence or absence of different aneuploidies in a sample |
US20130029348A1 (en) * | 2011-07-26 | 2013-01-31 | Opgen, Inc. | Methods of elongating nucleic acids |
WO2013016524A1 (en) * | 2011-07-26 | 2013-01-31 | Opgen, Inc. | Methods of elongating nucleic acids |
WO2013052913A2 (en) | 2011-10-06 | 2013-04-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10196681B2 (en) | 2011-10-06 | 2019-02-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11001884B2 (en) | 2011-10-06 | 2021-05-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10424394B2 (en) | 2011-10-06 | 2019-09-24 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10323268B2 (en) | 2011-10-06 | 2019-06-18 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11437121B2 (en) | 2011-10-06 | 2022-09-06 | Sequenom, Inc. | Methods and processes for non-invasive detection of a microduplication or a microdeletion with reduced sequence read count error |
US11492659B2 (en) | 2011-10-06 | 2022-11-08 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US9984198B2 (en) | 2011-10-06 | 2018-05-29 | Sequenom, Inc. | Reducing sequence read count error in assessment of complex genetic variations |
WO2013052907A2 (en) | 2011-10-06 | 2013-04-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3922731A2 (en) | 2011-10-06 | 2021-12-15 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11560586B2 (en) | 2011-10-06 | 2023-01-24 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US9367663B2 (en) | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3243908A1 (en) | 2011-10-11 | 2017-11-15 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US8688388B2 (en) | 2011-10-11 | 2014-04-01 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2013055817A1 (en) | 2011-10-11 | 2013-04-18 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2013073610A1 (en) * | 2011-11-15 | 2013-05-23 | ナガヤマ アイピー ホールディングス エルエルシー | Nucleotide sequencing apparatus |
JPWO2013073610A1 (en) * | 2011-11-15 | 2015-04-02 | ナガヤマ アイピー ホールディングス エルエルシーNagayama IP Holdings, LLC | Base sequence determination device |
WO2013109981A1 (en) | 2012-01-20 | 2013-07-25 | Sequenom, Inc. | Diagnostic processes that factor experimental conditions |
US11697849B2 (en) | 2012-01-20 | 2023-07-11 | Sequenom, Inc. | Methods for non-invasive assessment of fetal genetic variations that factor experimental conditions |
EP4148739A1 (en) | 2012-01-20 | 2023-03-15 | Sequenom, Inc. | Diagnostic processes that factor experimental conditions |
US20150011425A1 (en) * | 2012-01-27 | 2015-01-08 | Cornell University | Methods and arrays for controlled manipulation of dna and chromatin fragments for genetic and epigenetic analysis |
US9856513B2 (en) * | 2012-01-27 | 2018-01-02 | Cornell University | Methods and arrays for controlled manipulation of DNA and chromatin fragments for genetic and epigenetic analysis |
EP3757210A1 (en) | 2012-03-02 | 2020-12-30 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US9605313B2 (en) | 2012-03-02 | 2017-03-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10738359B2 (en) | 2012-03-02 | 2020-08-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP4155401A1 (en) | 2012-03-02 | 2023-03-29 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3401399A1 (en) | 2012-03-02 | 2018-11-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11312997B2 (en) | 2012-03-02 | 2022-04-26 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11306354B2 (en) | 2012-05-21 | 2022-04-19 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
WO2013184754A2 (en) | 2012-06-05 | 2013-12-12 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using dna origami probes |
US10497461B2 (en) | 2012-06-22 | 2019-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3473731A1 (en) | 2012-06-22 | 2019-04-24 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2013192562A1 (en) | 2012-06-22 | 2013-12-27 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP4137579A1 (en) | 2012-06-22 | 2023-02-22 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014011928A1 (en) | 2012-07-13 | 2014-01-16 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
US11332791B2 (en) | 2012-07-13 | 2022-05-17 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
WO2014014497A1 (en) | 2012-07-20 | 2014-01-23 | Verinata Health, Inc. | Detecting and classifying copy number variation in a cancer genome |
WO2014014498A1 (en) | 2012-07-20 | 2014-01-23 | Verinata Health, Inc. | Detecting and classifying copy number variation in a fetal genome |
US10482994B2 (en) | 2012-10-04 | 2019-11-19 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US12112832B2 (en) | 2012-10-04 | 2024-10-08 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3591067A1 (en) | 2012-10-04 | 2020-01-08 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014055774A1 (en) | 2012-10-04 | 2014-04-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014055790A2 (en) | 2012-10-04 | 2014-04-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP4009329A1 (en) | 2012-10-04 | 2022-06-08 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10497462B2 (en) | 2013-01-25 | 2019-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014116598A2 (en) | 2013-01-25 | 2014-07-31 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP4261828A2 (en) | 2013-01-25 | 2023-10-18 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP4414988A2 (en) | 2013-01-31 | 2024-08-14 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules using models of multiplicative form |
WO2014120819A1 (en) | 2013-01-31 | 2014-08-07 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules with interacting components |
WO2014120821A1 (en) | 2013-01-31 | 2014-08-07 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules using models of multiplicative form |
EP4398255A2 (en) | 2013-01-31 | 2024-07-10 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules with interacting components |
WO2014164838A1 (en) | 2013-03-12 | 2014-10-09 | Sequenom, Inc. | Quantification of cell-specific nucleic acid markers having a particular methylation state |
US9305756B2 (en) | 2013-03-13 | 2016-04-05 | Agena Bioscience, Inc. | Preparation enhancements and methods of use for MALDI mass spectrometry |
US11060145B2 (en) | 2013-03-13 | 2021-07-13 | Sequenom, Inc. | Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus |
WO2014168711A1 (en) | 2013-03-13 | 2014-10-16 | Sequenom, Inc. | Primers for dna methylation analysis |
US10204771B2 (en) | 2013-03-13 | 2019-02-12 | Agena Bioscience, Inc. | Preparation enhancements and methods of use for MALDI mass spectrometry |
EP3597774A1 (en) | 2013-03-13 | 2020-01-22 | Sequenom, Inc. | Primers for dna methylation analysis |
EP3409791A1 (en) | 2013-03-15 | 2018-12-05 | Verinata Health, Inc | Generating cell-free dna libraries directly from blood |
US10930368B2 (en) | 2013-04-03 | 2021-02-23 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014182726A2 (en) | 2013-05-07 | 2014-11-13 | Sequenom, Inc. | Genetic markers for macular degeneration disorder treatment |
US10699800B2 (en) | 2013-05-24 | 2020-06-30 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11462298B2 (en) | 2013-05-24 | 2022-10-04 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014204991A1 (en) | 2013-06-17 | 2014-12-24 | Verinata Health, Inc. | Method for determining copy number variations in sex chromosomes |
EP3543354A1 (en) | 2013-06-17 | 2019-09-25 | Verinata Health, Inc. | Method for generating a masked reference sequence of the y chromosome |
US10622094B2 (en) | 2013-06-21 | 2020-04-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3418929A1 (en) | 2013-09-27 | 2018-12-26 | Codexis, Inc. | Automated screening of enzyme variants |
US10964409B2 (en) | 2013-10-04 | 2021-03-30 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US11929146B2 (en) | 2013-10-07 | 2024-03-12 | Sequenom, Inc. | Systems for non-invasive assessment of chromosome alterations using changes in subsequence mappability |
WO2015061359A1 (en) | 2013-10-21 | 2015-04-30 | Verinata Health, Inc. | Method for improving the sensitivity of detection in determining copy number variations |
EP4227947A1 (en) | 2013-10-21 | 2023-08-16 | Verinata Health, Inc. | Method for improving the sensitivity of detection in determining copy number variations |
WO2015109234A1 (en) | 2014-01-16 | 2015-07-23 | Illumina, Inc. | Gene expression panel for prognosis of prostate cancer recurrence |
US11365447B2 (en) | 2014-03-13 | 2022-06-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3690061A1 (en) | 2014-05-30 | 2020-08-05 | Verinata Health, Inc. | Detecting, optionally fetal, sub-chromosomal aneuploidies and copy number variations |
WO2015184404A1 (en) | 2014-05-30 | 2015-12-03 | Verinata Health, Inc. | Detecting fetal sub-chromosomal aneuploidies and copy number variations |
EP3940703A1 (en) | 2014-07-18 | 2022-01-19 | Illumina, Inc. | Non-invasive prenatal diagnosis of fetal genetic conditions using cellular dna and cell free dna |
WO2016011414A1 (en) | 2014-07-18 | 2016-01-21 | Illumina, Inc. | Non-invasive prenatal diagnosis of fetal genetic condition using cellular dna and cell free dna |
EP3656875A1 (en) | 2014-07-18 | 2020-05-27 | Illumina, Inc. | Non-invasive prenatal diagnosis |
US11783911B2 (en) | 2014-07-30 | 2023-10-10 | Sequenom, Inc | Methods and processes for non-invasive assessment of genetic variations |
WO2016055380A1 (en) | 2014-10-09 | 2016-04-14 | Roche Diagnostics Gmbh | Mutations in the epidermal growth factor receptor kinase domain |
US11789906B2 (en) | 2014-11-19 | 2023-10-17 | Arc Bio, Llc | Systems and methods for genomic manipulations and analysis |
EP3502273A1 (en) | 2014-12-12 | 2019-06-26 | Verinata Health, Inc. | Cell-free dna fragment |
EP3567120A1 (en) | 2014-12-12 | 2019-11-13 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
WO2016094853A1 (en) | 2014-12-12 | 2016-06-16 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
US11929149B2 (en) | 2015-08-06 | 2024-03-12 | Arc Bio, Llc | Systems and methods for genomic analysis |
US10774375B2 (en) | 2015-09-18 | 2020-09-15 | Agena Bioscience, Inc. | Methods and compositions for the quantitation of mitochondrial nucleic acid |
WO2017136059A1 (en) | 2016-02-03 | 2017-08-10 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
EP3202915A1 (en) | 2016-02-03 | 2017-08-09 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
EP3517626A1 (en) | 2016-02-03 | 2019-07-31 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
US11200963B2 (en) | 2016-07-27 | 2021-12-14 | Sequenom, Inc. | Genetic copy number alteration classifications |
US11694768B2 (en) | 2017-01-24 | 2023-07-04 | Sequenom, Inc. | Methods and processes for assessment of genetic variations |
WO2018195483A1 (en) | 2017-04-21 | 2018-10-25 | Illuminia, Inc. | Using cell-free dna fragment size to detect tumor-associated variant |
WO2018236911A1 (en) | 2017-06-20 | 2018-12-27 | Illumina, Inc. | Methods and systems for decomposition and quantification of dna mixtures from multiple contributors of known or unknown genotypes |
WO2018236827A1 (en) | 2017-06-20 | 2018-12-27 | Illumina, Inc. | Methods for accurate computational decomposition of dna mixtures from contributors of unknown genotypes |
WO2019109086A1 (en) | 2017-12-01 | 2019-06-06 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
WO2022164968A1 (en) | 2021-01-29 | 2022-08-04 | Day Zero Diagnostics, Inc. | Methods for enriching microorganisms from low abundance clinical samples for dna sequencing |
Also Published As
Publication number | Publication date |
---|---|
US20100267154A1 (en) | 2010-10-21 |
JP2010539991A (en) | 2010-12-24 |
CA2701726A1 (en) | 2009-04-09 |
US20100267157A1 (en) | 2010-10-21 |
US20100268478A1 (en) | 2010-10-21 |
CN101889074A (en) | 2010-11-17 |
ZA201002881B (en) | 2011-07-27 |
MX2010003724A (en) | 2010-09-14 |
US20100267156A1 (en) | 2010-10-21 |
US20100267152A1 (en) | 2010-10-21 |
US8153438B2 (en) | 2012-04-10 |
EP2203547A1 (en) | 2010-07-07 |
US20100331195A1 (en) | 2010-12-30 |
AU2008308457A1 (en) | 2009-04-09 |
US20100267155A1 (en) | 2010-10-21 |
EA201000427A1 (en) | 2010-10-29 |
KR20100089060A (en) | 2010-08-11 |
US20100267153A1 (en) | 2010-10-21 |
EP2203547A4 (en) | 2011-06-01 |
IL204866A0 (en) | 2010-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8153438B2 (en) | Sequencing nucleic acid polymers with electron microscopy | |
EP3004385B1 (en) | Nanopore-based nucleic acid analysis with mixed fret detection | |
EP1543152B1 (en) | Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (spm) reading | |
EP1601791B1 (en) | Random array dna analysis by hybridization | |
EP1766081B1 (en) | Systems and methods of analyzing nucleic acid polymers and related components | |
EP3387108B1 (en) | Method of translocating nucleic acids through nanopores | |
JP2007175051A (en) | Oligomer array with pna- and/or dna-oligomer on surface | |
EP1711625A2 (en) | Methods and compositions for detecting nucleic acids using scanning probe microscopy and nanocodes | |
WO2013119784A1 (en) | Methods of sequencing nucleic acids using nanopores and active kinetic proofreading | |
US5470707A (en) | Hydrogen bond labeling and base sequence determination methods for DNA or RNA | |
EP1546983A2 (en) | Controlled aligment of nano-barcodes encoding specific information for scanning probe microscopy (spm) reading | |
US20050164211A1 (en) | Carbon nanotube molecular labels | |
DK2217729T3 (en) | Method of concentrating nucleic acid molecules | |
CN102640000B (en) | Adopt improving one's methods of secondary ion mass spectrometry (SIMS) high-sensitivity detection and quantitative biomolecule | |
WO2010144128A2 (en) | Molecular alignment and attachment of nucleic acid molecules | |
Simion et al. | Detection of human papilloma viruses using nanostructurated silicon support in microarray technology | |
WO2023130019A2 (en) | Spatial omics platforms and systems | |
WO2017075179A1 (en) | Sequencing by deconvolution | |
JP2004061170A (en) | Measuring method using dna chip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880119334.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08835273 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010528215 Country of ref document: JP Ref document number: 201000427 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1884/CHENP/2010 Country of ref document: IN Ref document number: MX/A/2010/003724 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008308457 Country of ref document: AU Ref document number: 204866 Country of ref document: IL Ref document number: 2701726 Country of ref document: CA Ref document number: 584432 Country of ref document: NZ |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008835273 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107008686 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2008308457 Country of ref document: AU Date of ref document: 20081006 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12681589 Country of ref document: US |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0818172 Country of ref document: BR Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL, TENDO EM VISTA A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL FACE A INTEMPESTIVIDADE, POIS O PRAZO PARA A REFERIDA ENTRADA EXPIRAVA EM 04/04/2010 (30 MESES CONTADOS DA DATA DE PRIORIDADE) E A PRETENSA ENTRADA SO OCORREU EM 06/04/2010. |